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A. MEDICINAL ARSENICAL CANCER.
I. Historical.
THE first observer to direct general attention to the role of arsenical drugs
as an etiological factor in cancer of the slkin was Sir Jonathan Hutchinson.*
He described in 1887/88 five cases leading him to the idea that the internal
administration of arsenic in large doses over long periods might produce a form
of cancer which presents certain peculiarities. In all cases a condition of local
keratosis had preceded the cancer; in one case the cancerous ulcer had developed
on rough skin on the side of the trunk, in one case on a corn on the scrotum,
whilst in all the others it occurred in keratotic areas on the hands or feet.
In the following years the views of Hutchinson were discussed. An always
rising number of similar cases was reported. Hartzell (1899) was able to collect
10 cases; Wile (1912) 19 cases; Pye-Smith (1913) 31 cases, 24 of them of
apparently medicinal origin. Nearly all authors (Hartzell, 1899; Ullmann, 1900;
Schamberg, 1907; Dubreuilh, 1910; Pye-Smith, 1913; Bland-Sutton, 1916; Wise,
1920) agreed with the teaching of Hutchinson. Wile (1912) made an "impartial
statement" of the facts for and against the specificity of arsenical cancer. Only
a few authors, as de Silva (1918), opposed the views of Hutchinson; de Silva
admitted that arsenic is responsible for the production of the keratotic condition,
but regarded the development of cancer as being independent.of the drug.
Eventually the views ofHutchinson were accepted by all dermatologists.
Then the predominance of a history of psoriasis in cases of arsenical cancer
was especially discussed (see p. 194).
A new period in the history of medicinal cancer started with the establish-
ment and characterization of the clinical picture called multiple superficial
epitheliomatosis, and the discussion of the etiological role of arsenic in this
condition. These discussions mainly in the dermatological societies since about
1930 have not yet led to general agreement (see p. 201). The same is true
* Preceding the appearance of Hutchinson's report several authors had already described the
occurrence of cancer of the skin in cases of psoriasis (Pozzi, 1874; Tillaux, 1877; Cartaz, 1878;
WVhite, 1885; and Hebra, 1887; cit. Pye-Smith, 1913b); but they had not associatedthedevelopment
of cancer in these cases with the previous administration of arsenicals for treatment.
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concerning the condition called Bowen's disease and extramnammillary Paget's
disease and their relations to ingestion of arsenic. It was tried to clear these
questions by the application of chemical and especially histochemical methods
of investigation for arsenic in the growths and in the unaffected skin of the
patients.
In Table I are collected 143 published cases of medicinal arsenical epithe-
lioma in man. Not included are:
(a) About 13 cases in which neither the original paper nor a reliable
abstract could be obtained : Toeroek, 1891; Crocker-Hartzell, cit. Hartzell,
1907; Foenss, 1921, 1923 (two cases?); Schaumann, 1922, 1923;
Papagaaw, 1926; Urbach, 1926; Ullmann, 1930, 1933; Mayer, 1933;
Schaerrer, 1934 Simons, 1936/37; Zieler, 1938, cit. Voss, 1939; Koerbler,
1939; Rille, cit. Voss, 1939; Hauser and Simon, 1941.
(b) Cases published without detail: Spencer, 1913; Oliver and
Finnerud, 1928, "case 2"; Montgomery, 1935 (about 11 cases); Rosen,
discussion to Montgomery, 1935 (several cases); Cannon, discussion to
Montgomery, 1935; Nomland, cit. Waugh and Scull, 1935 (two cases);
Anderson, discussion to Montgomery and Waisman, 1941 (a number of
cases); Gammel, discussion to Barney, 1944; Ellis, discussion to Ander-
son and Burpeau, 1945 (two cases); Roxburgh, discussion to Russell
and Klaber, 1945.
(c) About 15 cases in which the administration of arsenicals is either
doubtful or not mentioned at all, but may be assumed as probable:
Pozzi, 1874, Tillaux, 1877; Cartaz, 1878; Whitfield, 1906; Sargent,
1906; Wende, 1908; Remnenovsky, 1921 ; Ketron, 1927 (two cases);
Dreyer, 1927, cit. Buergener, 1939; Stillians, 1930, cit. Anderson, 1932;
Cheever, 1931, cit. Buergener, 1939; Franseen and Taylor, 1934 (5 cases,
"cases 11-15"); Guszman, 1934, cit. Buergener, 1939; Opfer, 1935,
cit. Buergener, 1939; Montgomery and Waismnan, 1941, "case 3."
(d) Four cases in which the diagnosis cancer (epithelioma) is not
certain: Schamberg, 1907, "case 2 "; Sawyer, 1929; Lane, 1939;
Abramowitz, Mattice and Bottvinck, 1944, "case 8."
(e) Seven cases in which besides arsenic other potential carcinogenic
agents (X-rays, radium) were used: Schwartz and Busman, 1924
(X-rays); Mayer, 1927, cit. Buergener, 1939 (X-rays); Stillians, 1931;
Blumenthal, 1931, cit. Buergener, 1939 (X-rays); Milch, 1932 (radium);
Glen, 1945 (radon); Anderson and Burpeau, 1945 (X-rays).
II. Diseases for which Arsenical Drugs were taken.
Considering the vast number of conditions in which arsenic is used for long
periods, the great percentage of cases in which arsenical cancer has developed in
patients suffering from skin-diseases (in 89 = 71 2 per cent), and especially from
psoriasis (in 67 53.6 per cent),' of all cases with noted diagnosis, is very
impressive. It seems to be more than a mnere coincidence. Hartzell, 1899; Wile,
1912; Alexander, 1921; Remenovski, 1921; Templeton, discussion to Alderson
(1935); and Buergener, 1939, have discussed this question (see p. 200). On the
other hand the number of cases developed in arsenic-treated cases of different
internal disorders is relatively small; surely some of these diseases may have
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Out of the 143 cases in Table I, the disease for which arsenic has been ad-
ministered is mentioned in 125 cases:
For Psoriasis
Pemnphigus .
Eczema, Dermatitis
Dermatitis herpetiformis
Acne .
Lichen ruber
Pruritus
Unknown disease of skin
67
3
. . . 4
· *· . 6
· ~ · ~ . 1
· ~ · ~ . 1
. ~ . . 3
cases . . 53 6 per cent
I 22 cases, 17.6 ,,
Sum of cutaneous diseases .
Anaemia and haemnorrhagic diathesis
Asthma and chronic bronchitis
"Stomach trouble"
Epilepsy and "fits" .
Chorea.. .
Ataxia(?) . . .
Nervousness .
As "tonic" and for "complexion"
Malaria . . .
"Syphilis" . . .
Sum of diseases without diseases
of the skin
Diseases not known in .
89 cases. 71 2
4 cases.
6 ,,
1
11 ,,
3 ,,
1 ,,
3 ,,
4 ,,
1 ,,
2 ,,
36
17
28.8
100 ,,
ended with death before an arsenical cancer had time to develop as in cases of
pernicious anaemia, leukaemia, and Hodgkin's disease; butthisexplanationwould
not be valid for the less dangerous forms of anaemia, for asthmia and the great
number of patients with asthenia in which prolonged and repeated medication
with arsenic is or was in common use. And the appearance of arsenical cancer
as a sequel to treatment of syphilis with arsenicals is really a rarity. Only 2 or
perhaps 3 cases (50, 53, 108 ?) are contained in Table I. Besides, Cannon (discus-
sion to Montgomery, 1935) mentioned several patients with multiple basal-celled
epitheliomas who had received injections of arsphenamine for syphilis, but no
details were given. Spenicer (discussion to Pye Smith, 1913a) mentions another
case.
So it seems that affections of the skin, and especially psoriasis, give a pre-
disposition for arsenical cancer, although there is no real definite proof.
III. Sex of the Patients.
In 131 cases of Table I the sex is noted; 91 were males and 40 females;
that means a sex relation of 2 3 : 1. This predominance of males is not a
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characteristic of arsenical cutaneous cancer, as it is found in cancer of the skin
in general.
IV. Arsenical Drugs Used.
In nearly all cases inorganic drugs were used, containing arsenic in its trivalent
form; that means derivatives of arsenious acid, the most common drug being
potassium arsenite KAsO2; it was mostly given in aqueous solution (1 per cent
calculated as As203 =Fowler's solution), or as arsenious anhydride = arsenic
trioxide As203 in form ofthe so-called asiatic pills black pills (each containing
usually -L gr.), or as Donovan's solution (containing 1 per cent AsJ3 plus 1 per
cent HgI2. In two cases "Ascato" was taken, a patent medicine for the treat-
ment of asthma; in one case "Dr. Greene's Nervinum." Nearly always the
drugs were ingested by mouth; in two cases they were also injected.
Pentavalent inorganic compounds-derivatives of arsenic acid, H3AsO4, are
not in use as medicaments; so it is not surprising that no case is known in which
arsenical medicinal cancer has been observed on this basis; but, as it is known
that pentavalent arsenicals are reduced in the body into trivalent ones (see
p. 230), it can be understood that they play a role in occupational cancer (see
p. 217).
Some confusion has arisen in the literature of arsenical cancer about the
denominations "trivalent" and "pentavalent." It seems to be a mistake that
Osborne (1925, 1928) quotedAs in arsenious acid as "quintavalent" (pentavalent),
and some authors (Milch, 1932; 'McNeer, 1934, and Montgomery, 1935) followed
him. Generally arsenious acid is considered as trivalent, although some reasons
may be produced for its being pentavalent in the vitreous arsenious anhydride
(Erdmann, 1904).
The most important trivalent organic arsenical compounds, the arsphenamins
so generally used in the treatment of syphilis, play only an insignificant role in
the causation ofcancer. It is true that arsenical keratoses after their administra-
tion have been observed repeatedly (MacLeod, 1913; Gauvin, 1927; and Timber-
lake, 1929). Spencer, discussion to Pye-Smith (1913a), was told of a case of
arsenical epithelioma traceable to salvarsan, and Galloway (ibid.,) and Ullmann
(1917) have sounded warnings that more incidences might be expected. In
the case of Harbitz, 1927 (case 53), after injections of arsphenamine a malignant
tumour developed at the site of the injection, a fibrosarcoma, different from
the usual kind of arsenical cancer. Rosen (discussion to Montgomery, 1935)
has seen several cases in which the treatment ofsyphilitic affections ofthe mouth
with arsphenamine had led to the development of epitheliomas of the oral
mucosa. Cannon (ibid., 1935) has observed basal cell epitheliomas in several
patients who had received many injections of arsphenamine a number of years
before. Besides, arsphenamines were administered in the cases of Levin (1926)
(case 50) and of Milch (1932), but in combination with trivalent inorganic
arsenicals. For Ebert's (1929) results with intradermal application of arsphena-
mine see p. 226, Experimental Arsenical Cancer.
Some pentavalent organic arsenicals as cacodylates, atoxyl and arsacetine
are- or were-frequently used as medicaments; but it seems that they never
have proved as carcinogens; only in case 135 possibly cacodylates were used.
No case in known in which external application of arsenic as medicament
(as a caustic, e.g. in lupus, or in the odontologic practice) has produced a cancer.
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V. Duration of Administration of Arsenic.
Duration ofexposure toarsenicin casesofmedicinalarsenicalcancer is reported
only in a certain number ofthe cases. Among 96 cases ofTable I the distribution
was as follows:
6 weeks . .. 3 cases.
2 months . . . . . . 1 case.
6 ,, . . . . . . 4 cases.
Up to 1 year . . . . . 3 ,,
1-5 years . . . . . . 22 ,,
6-10 years . . . . . . 13 ,,
11-20 ,, . . . .... 16 ,,
21-30 ,, . . . . . . 8 ,,
More than 30 years . . . . 4 ,,
"A short time" . . . . . 2 ,,
"A considerable time". . . . 1 case.
"From time to time . . . . 1 ,,
"Several years" . . . . . 4 cases.
"Many years" or "long time" . . 16 ,,
98 ,,
Inthe great majority cancerresulted onlyafterthe drughad beenadministered
for a very long period, up to 36 years (case 38). But there are also cases in which
a veryshorttimeofexposurewassufficientforthelaterdevelopment ofmalignancy
(cases 37, 79, 91, 123 and 128).
VI. Quantity of Arsenic Taken.
Similar great differences can be noted in comparing the doses of arsenic
leading to the development of malignancy. Only in about 16 of the patients in
Table I the doses and the time of administration are sufficiently noted; in one
case (case 83) a quantity of only 0.19 g. As203 was given, whereas case 23
received in all about 70 g., and case 124 about 121 g.. The average
quantity was about 28 g.-about 430 grains.*
VII. Symptoms of Arsenicism Preceding and Accompanying
Arsenical Cancer.
The development of arsenical cancer is frequently-often for many years-
preceded by non-malignant manifestations of arsenicism. Some of these seem
to be without any direct relation to the origin of malignancy, whereas others,
especially the keratoses, often give rise to the appearance of cancer, and have,
therefore, to be regarded as really "precancerous" manifestations.
Only rarely signs of acute arsenical poisoning are mentioned in the history;
and even certain usual signs of chronic arsenicism, as neuritis, anaemia, nephritis
and affection of the liver, have been observed in only a few of the patients with
arsenical cancer.
* It is supposed that Fowler's solution, given in the great majority of cases, was always un-
diluted (1 per cent As203).o0. NEUBAUER
A sign of chronic arsenicism in those patients, often but not constantly
reported, is hyperpigmentation (melanosis) of the skin. The patients exhibit
a brownish-yellow tint usually most marked in places which normally are
more pigmented (areolae of the nipples, about the axilla, in the groins, on the
perineum, etc.), and in sites of pressure (waist of women, beneath the garter,
etc.), and on previous lesions of the skin. The pigmentation occurs in patches,
often forming reticular mottling, or showing a "rain-drop "-like appearance.
The pigmentation is not unlike that in Addison's disease; but in this condition
the affected skin is not so harsh and scaly, and often the mucous membranes
are affected too (in arsenical melanosis only exceptionally).
In 25 of the cases in Table I hyperpigmentation is noted; but there mnay be
many more inwhich it was present. Only in 11 cases the absence ofpigmentation
is definitely stressed.
Other changes of the skin reported are: telangiectases (cases 20, 85, 117
and 124), chronic arsenical dermatitis (case 48), erythrodermia (case 47), erythro-
dermia exfoliativa (cases 51, 69 and 70), multiple seborrhoeic warts and molluscum
fibrosum (cases 140 and 141), seborrhoeic keratoses (cases 74 and 75), and affections
of the nails (see Willcox, discussion to Hamilton, 1921).
But by far the most important manifestations preceding the appearance of
arsenical cancer are keratoses. Henoch and Romberg in 1851 (Geyer, 1898) have
recognized epidermic desquamation of palms and soles as a sequel to the internal
use of arsenic, and in 1868 Erasmus Wilson has given a specified description
of this condition. Hutchinson (1887) has emphasized their importance as
precursors of arsenical cancer. (Pictures, see Hutchinson, 1888, plates xxi and
xxii, 1895, plates xvii and xix.)
These keratoses occur especially on the palms and soles, but may be found
anywhere on the cutaneous surface. The most characteristic form, the nodular
form (punctate keratosis) of the palms and soles, is marked by numerous small
horny corn-like elevations usually 2-5 mm. in diameter. They occur frequently
as epidermal pegs which can be picked out of their keratotic beds. They are
frequently situated on the thenar and lateral borders of the hand, on the roots
or on the side surfaces ofthe fingers, sometimes also on the back of the phalangeal
joints. On the feet the sites of prediletion are the heels and the toes. There
may be a confluence of a group of these corns forming wart-like excrescences, but
differing from true warts by having no papillary structure. Sometimes the
palms only or the soles only are affected. In other cases there is a more diffuse
keratosis of the palms and soles, giving the skin a leathery appearance, often
accompanied with or preceded by hyperidrosis. The horny thickenings may be
situated on an erythematous base, or a horny patch may be surrounded by an
erythematous halo. Frequently the diffuse form of keratosis is combined with
the nodular form.
The keratoses of palms and soles are usually 'symmetrically distributed.
Fissures are liable to occur on the keratoses.
Slight keratoses may also occur on other parts of the body, rendering the
skin harsh, or flat reddish erythematous patches, or scaling keratotic plaques may
be found. They occur mostly on the unexposed parts of the body, in contra-
distinction to the keratoses of senile and of weather-beaten persons.
These keratoses are present in the great majority of cases of arsenical cancer.
They are noted in 116 out of the 143 cases of Table I. In only 10 cases their
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presence is denied; all these are apparently cases of superficial epitheliomas
(see below), one perhaps a true psoriasis cancer (case 24, see below). In the
remaining 18 cases nothing is said about keratoses, the histories often being
short and deficient. So it can be stated that keratoses occur in from 81 to 93 per
cent of all cases of arsenical cancer. Hands or feet or both were involved in at
least 97 cases, mostly in the classic form of corns on palms and soles, frequently
combined with keratoses on other parts of the body. In only two or three cases
keratoses were present but spared hands and feet. In case 74 a keratosis
appeared in the form of a cutaneous horn in the right groin; in case -i7 a distinct
hyperkeratosis subungualis is noted. Leikoplakia oris was present in cases
33 and 129.
The keratoses develop gradually, and may not appear for some time after the
ingestion of arsenic. The interval between the beginning of exposure to the
poison and the appearance of keratotic lesions is very different in different cases.
(See p. 210, Chronological Course.)
Many of the keratotic areas become stationary, or may even undergo a
gradual involution after the use of the drug has been stopped (Montgomery,
1935). But some of them develop progressive changes-painful fissures, in-
fections, etc.--and eventually may give rise to malignant growth; in some cases
the malignancies originate on other parts of the body (see below). Montgomery
(1935) states that out of his 85 cases of arsenical keratosis 20 per cent developed
epitheliomas.
The multiple horny keratoses, especially the punctate or warty form on the
palms and soles, are generally recognized as being pathognomonic for chronic
arsenical poisoning; they can be confounded only with certain hereditary forms
of keratosis punctata. Nearly all dermatologists agree that their mere presence
justifies the diagnosis of arsenicism even in cases lacking any history of ingestion
of the poison (see Franseen and Taylor, 1934; Oliver, discussion to G. Lane,
1939; and Montgomery and Waisman, 1941, "case 3 "). Hence their great
importance for the diagnosis-as real "leading fossils " for prophylactic
therapy and for the consideration of the pathogenesis.
VIII. Clinical Pictures of Medicinal Arsenical Cancer.
The development and appearance of arsenical growths are by no means the
same in all cases. There are several types differing in localization, in the grade
of malignancy, in the histological picture, etc.
1. Arsenical epithelioma of the skin developing in keratotic areas (Hutchinson type
or keratoseogenic cancer).
These cases, described in such a classic manner by J. Hutchinson, form a
most characteristic group. After the keratotic lesions, especially those of the
hands and feet, have existed for a long time, sometimes for years, oneofthem-or
some ofthem-begin to undergo certain changes: they become painful, bleeding
fissures appear, and after a certain time, sometimes after years, an ulcer appears
with hard pearly borders slowly extending without tendency for healing.
Histological examination shows an epithelioma usually of the squamous cell
type. Sites of predilection are the hands, especially the fingers, palmar and
lateral surfaces, thumb, the borders of the palms, the heel and toes, but any
14
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arsenical keratosis may give rise to such a malignant degeneration. At the same
time or later another malignant ulcer may appear on a keratosis in the vicinity
or elsewhere, or even in a non-keratotic area; and then another and so on.*
Ifnottreated in time,earlier or later the regionallymph-nodes becomeinfiltrated,
and death occurs with the signs of general marasmus. Practically all such
cancers arising on pre-existing arsenical keratoses are squamous-celled in type.
The first microscopical changes in the. malignant alteration of the keratoses
consist of keratinization and vacuolization of. individual cells in the epidermis
(malignant dyskeratosis); further, the continuity of the basal layer becomes
destroyed (see Montgomery, 1935, fig. 2b and 3). Arsenic can be found regularly
by the Osborne method, and sometimes also by the chemical method (see
p. 211, Chemistry and Histochemistry).
This type of arsenical cancer, the "Hutchinson type," is the earliest known,
the most characteristic, and is very frequent. Nearly all cases reported until
1910 belong to it. Wile wrote still in 1912: "It is highly probable that all
arsenical epitheliomata develop from keratotic nodules." About the frequency
of this type see below, Frequency of Different Types.
2. Arsenical epitheliorna arising in a patch of psoriasis.
In a few of the cases in which malignancy developed in cases of psoriasis
treated with arsenic, the cancer originated from a psoriatic patch: cases 23, 32,
39, 43, 138 and possibly also 7 and 46.
The occurrence of cancer in cases of psoriasis attracted attention even before
Hutchinson had discovered the carcinogenic property of arsenic (see above,
p. 193). Hartzell (1899) collected a series of cases, and recognized that in nearly
all cases there was evidence of prolonged arsenical treatment and presence of
arsenical keratoses. So he arrived at the opinion that in these cases the cancer
is a result of arsenical treatment and not of psoriasis. And as the malignancy
nearly always developed on the keratoses, it was thought that all incidences of
cancer in psoriasis were due to arsenic; not to the psoriasis. On the other
hand Wile (1912) stressed the especially high incidence of psoriatics amongst
the patients with arsenical cancer: "Considering the vast numbers of condi-
tions . . . in which arsenic is employed, it seems more than a coincidence
that of 19 cases, 15 have occurred in conditions (14 of them psoriasis and 1
pemphigus), in which an abnormality of epithelial growth ante-dated the use of
the drug." In the same year Gray (1912) published a case of rodent ulcer
originating in a patch of psoriasis (case 24). The patient had taken arsenic but
without developing arsenical keratoses. Alexander, collecting all 17 cases of
cancer in psoriatics, published until 1921, and adding one case ofhis own, tried to
classify them in two groups:
1. Cases of true or genuine psoriasis-cancer (" echte Faelle von
Psoriasis-krebs ") in which a direct transition of a (mostly single) psoriatic
patch in cancer is evident or very probable; here arsenic may not play
an etiological role. There may be no history of ingestion of arsenic;
keratoses may be absent. These cases are very rare.
2. Cases of arsenical cancer in psoriatics: The malignancy originates
on an arsenical keratosis or on other (non-psoriatic) sites, often multiple
* Pictures, see Hutchinson, 1895 and 1903; Montgomery, 1935, etc.
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from the beginning. History of arsenic ingestion; arsenical keratbses
are present.
Remenovsky (1921), publishing in the same year a case of true psoriasis
cancer (arsenic had been taken, but it seems after the beginning of malignancy),
emphasized the extreme rarity of such observations.
Buergener, in 1939, in a critical review goes even so far as to say that agenuine
psoriasis-cancer does not seem to exist. In nearly all the cases in which it may
be supposed the influence ofprevious treatment with carcinogenic agents (arsenic,
X-rays, radium) may have been of importance. In the remaining very few
incidences there may be a chance of an accidental coincidence (two examples
are given).
So even in these cases in which the malignancy has developed in a psoriatic
lesion, arsenic as a causative agent may be assumed if arsenic has been given
(cases 7, 24, 32, 39, 43, 46 and 138), or if its presence is proved by chemical or
histochemical methods or if typical arsenical keratoses are found (cases 39,
43 and 46). On the other hand the coincidence ofpsoriasis and arsenical cancer
-including the multiple benign superficial epitheliomas (see below)--is so
frequent that some connection, e.g. a predisposition of psoriatics for cancer of
the skin, is supposed by many observers (Wile, 1912).
Besides, it must be kept in mind that sometimes other lesions, especially
erythematous plaques of superficial epitheliomatosis, are mistaken for psoriatic
plaques (Pfahler, 1927; Montgomery, 1929; Wright and Friedman, 1933;
Ellis, discussion to Anderson and Burpeau, 1945); even some forms of true
cancer bear a striking clinical resemblance to lesions of psoriasis-psoriasiform
basal cell carcinoma (see Sutton, 1939).
3. Arsenical epitheliornas in normal skin.
Wile wrote in 1912: "It seems highlyprobable that all arsenicalepitheliomata
had their starting-point in keratotic nodules; in no case is there evidence of ar
epithelioma arising from the unbroken normal skin." This view cannot bJ
maintained further.
So in Lane's (1894) case (case 7) the first growth appeared on the forearm in
apparently healthy skin. It seems that not seldom in the same patient some
malignancies arise on keratoses and others on normal skin; but unfortunately
precise notes on this point are missing in the majority of cases; frequently
nothing is said about the previous appearance of the skin. Further, there is
no doubt that the lesions of typical multiple superficial epitheliomas regularly
develop in previously normal skin of the trunk and the proximal parts of the
extremities (see below).
4. Multiple (benign) superftcial epitheliomata.
(Multiple carcinoids, Arning, 1922; erythematoid benign epithelioma,
Graham Little, 1923; epithelioma erythematoides benignum, Montgomery,
1929 and 1935; carcinoma cutis multiforme; epitheliomatosis.*)
This form ofepithelioma ofthe skin and its relation to arsenic have attracted
special interest since about 1930.
* Japeway as far back as 1910 gave a clinical and histological description of this type ofepithe.
lioma (Gross, 1931).
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It is characterized by the eruption of multiple (usually numerous) superficial
epitheliomas in the form of slightly depressed red patches mostly on the trunk
and the proximal parts of the extremities, but neck and head, including the
scalp, may also be affected. The lesions vary from ill-defined seborrhoea-like
crusts tolesions several centimetres orevenmoreindiameterwiththick, verrucous,
hard, dirty crusts. The removal of the covering crusts reveals a wide rolled
indurated pearly border, in typical cases a very faint white wax-like narrow
raised margin, flatter than the rolled edge of the lesions in the more malignant
forms of epithelioma. (For pictures, see Montgomery, 1929 and 1941.)
Histologically the condition usually shows the picture of basal-celled epithe-
lioma, but sometimes squamous-cell epithelioma and mixed types may be found
(see below).
The affection is benign in character; absence ofulceration over long periods;
long duration-10, 20, 30 years and even more; the lesions sometimes dis-
appearing spontaneously; no metastases. Hence this kind of epithelioma
apparently cannot be called a real cancer. But occasionally in the centre of
a plaque a fungating squamous-cell epithelioma may develop, resulting
eventually in metastases and death; and besides, not infrequently they
associate with other malignant kinds of epidermal growth, e.g. the Hutchinson
type of arsenical cancer.
Graham Little (1923) has mentioned the fact that this condition also fre-
quently affects psoriatics, and many others have confirmed this observation:
Ormsby and Mitchell (1925), Stillians (1931), Senear (discussion to Stillians, 1931),
Wright and Friedman (1933), Parkhurst (discussion to Arday, 1938), Applestein
(1941), and Ellis (discussion to Anderson and Burpeau, 1945).
There is considerable controversy regarding the etiological role that arsenic
plays in this type of epithelioma.
In 1931 Stillians and Gross presented patients with typical multiple epithe-
liomas who were treated previously with arsenic (cases 66 and 68). Andrews
(1932), reporting another case (73), stressed this fact; he admits that this fact
alone is no proof for the etiological role of arsenic. On the other hand, he
succeeded in his case in demonstrating arsenic in the tissue.
Anderson in 1932 reported three cases with exposure to arsenic (in the second
case an occupational one), with keratoses of palms and soles; in two of his
cases (74 and 75) arsenic was detected in the urine; in one (74) a small quantity
also in the tissue. Anderson summed up all points speaking in favour of an
etiological role of arsenic in the great majority of cases of superficial epithe-
liomas: v
1. The frequent history of previous exposure to arsenic; of course
that is true for all cases of Table I, as this contains only arsenic-treated
cases.
2. The frequent simultaneous occurrence of hyperkeratosis of the
palmns and feet, similar to that in the Hutchinson type of cancer. Among
the about 46 uncombined cases in Table I, in 29 the presence of keratoses
is stated (but only in 23 location of the keratoses on the hands and feet);
in 9 cases their absence; in 8 cases nothing is noted about keratoses.
So the typical keratoses of hands or feet were present in at least 50 per
cent of the cases. In one case (64) they started before the appearance of
the epitheliomas, in case 74 later.
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3. The fact that a considerable number of these patients had psoriasis
and were treated for it, or for a condition mistakenly diagnosed as
psoriasis (see above, pp. 200-201) Among the 46 patients with un-
combined superficial epitheliomas in Table I, at least 21 were treated
with arsenic for psoriasis. The question whether this treatment is
responsible for the epitheliomas or if there is something in psoriasis itself
that tends towards the development ofthese lesions was discussed in 1931:
Senear cited two cases in which the ingestion ofarsenic could be ruled out.
Pigmentation of the skin of arsenical type is noted in 9 out of the 46
uncombined cases in Table 1.
In subsequent papers Anderson (1937, 1943a, 1943b and 1945) stuck
to his opinion. In the discussion to Montgomery's lecture in 1941 he reported
some 40 cases of superficial epitheliomas with arsenical keratoses of palms and
soles; in one case at least arsenic was found in the urine. A similar case of
Anderson and Burpeau (1945) is not included in Table I because X-rays were
also administered.
Ayres (1934 and 1943), confirmed the views of Anderson by reporting two
cases apparently caused by arsenic (85 and 131). Ayres and Anderson
(1934) reported that in examining 44 patients with basal-cell epithelioma-most
of them may be supposed to belong to this type-they found punctate keratoses
in 75 per cent. Among 19 cases 12 were demonstrated to have arsenic in the
urine, and in six others there was a history of exposure to arsenic.
Wright and Friedman (1933), reporting five casesofsuperficial epitheliomatosis
in psoriatics, three of which had used arsenic, denied the etiological role of that
drug because none of these patients had keratosis or pigmentation, and arsenic
could not be demonstrated by Osborne's method.
Halloran (discussion to Anderson, 1937) and Traub (1937) supported the
view of Anderson. Arday (1938) seems to doubt whether arsenic is a causative
factor in such cases, whereas Parkhurst (discussion to Arday, 1938) assumes a
relation. Cannon's (discussion to Montgomery, 1935) patients with multiplebasal-
cell epitheliomas gave in the great majority of cases a history of ingestion of
arsenic, and had large quantities of arsenic in blood, urine and skin.
Montgomery (1935 and 1941), with the enormous experience of the Mayo
Clinic, denied the etiological role of arsenic in true benign epitheliomatosis. He
emphasized that the cases of multiple superficial epitheliomas have to be
differentiated in two distinct groups:
1. The multiple benign superficialepitheliomatosis proper, characterized
especially by a fine threadlike slightly elevated border of the lesions and
by benign character, most of the lesions being of the basal-cell type
.(picture, Montgomery and Waisman, 1941, fig. 5). Amongst 65 cases of
this group (16 described in 1929 and 49 in 1935) only one patient re-
membered to have taken arsenic. So Montgomery does not believe in
arsenic as a definite cause of this condition.'
2. The secondary form of multiple superficial epitheliomas arising
also from non-keratotic areas and occurring also with predilection for the
trunk, but marked by simulating lesions of arsenical keratosis, especially
by a wide rolled indurated (not a threadlike) border, and tendency to
malignancy (picture, Montgomery, 1935, pp. 223, 373, and 1941, fig. 4).
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Histopathologically they are mostly squamous epitheliomas, butsometimes
also basal-celled ones are found (Montgomery and Waisman, 1941).
Nearly all cases of mniltiple superficial epitheliomas with a previous
history of arsenic or with keratoses of palms and soles are put by Mont-
gomery together with this group, setting them apart from true benign
epitheliomatosis. Evidence of pigmentation he noted only in a few of
these cases. Attributing to arsenic a very important etiological role he
described these cases as "arsenical type of epithelioma," a name which
may cause confusion with the keratoseogen Hutchinson-type of arsenical
epithelioma. Montgomery reported 7 cases in 1935 (e.g. cases 103, 104
and 105) and 4 in 1941 (e.g. cases 127 and 128). Fraser (discussion to
Wise, 1929) supported Montgomery's distinction of two groups of epithe-
liomas of the trunk.
Montgomery tried to prove his view by chemical analysis. In the growths
of the second group he found regularly a considerable amount of arsenic by
the chemical as well as by the Osborne method (cases 104, 105, 127 and 128).
He lays stress especially on the fact that the growths contained more arsenic
than the adjacent normal skin of these patients; whereas in the lesions of the
true benign group, in the great majority of cases none or little was found, in any
case less than in the normal skin.
Montgomery does not deny any relation of benign epitheliomatosis to arsenic.
He admitted that in some cases arsenic may be detected by Osborne's method
(1935 and 1941). Further, he himself stated in 1935 that the two types of
epithelioma may be associated in the same patient, as in 7 of the 16 cases of
"arsenical type of epithelioma" (e.g. case 106). But he suggests that in such
cases arsenic is not the cause of the benign epithelioma, but presumably only
precipitates its development caused by an unknown predisposition.
There is no doubt that many of Anderson's and Ayres' patients belong to
Montgomery's second group, the "arsenical type of superficial epithelioma";
but at least some of their cases seem to be true benign epitheliomas. Anderson
(1937) doubts whether the distinction between the two groups is really practic-
able; he "cannot see how anyone can make such a hair-line distinction as
regards the border."
Most authors agree now that at least a proportion of superficial basal-celled
epitheliomas are caused by arsenic. Opinions differ mainly as to how great this
proportion is; whether nearly all incidences of this condition are due to arsenic
(Anderson and Ayres), or many of them (Barber, 1939; MacCormac, discussion
to Barber, 1939), or a certain percentage (Bloom, 1936; Gray, discussion to
Barber, 1939) or only a few (Mumford, ibid., 1939). Andrews (1932) thinks that
arsenic may be supposed to play an etiological role, but there is no real proof.
Barker (discussion-to R. M. Montgomery, 1942) reported lately a high content of
arsenic in the blood of such patients.
In a very high proportion of cases multiple superficial epitheliomas were
associated with other forms of arsenical cancer (see p .207, Frequency of the
Different Types).
Another type of epithelioma is mentioned by Cannon (discussion to Mont-
gomery, 1935): basal-cell epitheliomas on the face of comparatively young
persons recurring at intervals ofseveral years in different locations, with presence
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of large quantities of arsenic. But no details of the histories are given, and the
author himself finds it difficult to evaluate the presence ofarsenic.
5. Bowen's disease.
Much confusion has arisen in the last twenty years about "Bowen's Disease"
and its relations to arsenic.
Bowen, in 1912, described an extremely chronic affection of the skin with
atypical epithelial proliferation as a new type of "pre-cancerous dermatosis."
This Bowen's disease is marked clinically by multiple slightly elevated papules
of dull-red colour, covered with scaly crusts, and arranged in groups-often
with arciform configuration---or as multiple lenticular plaques. The histological
picture is described as a neoplastic process with abnormal keratinization,
"malign dyskeratosis" (Darier, 1914-15 and 1920), and amitotic cell division
producing giant cells. The changes are often similar to those in arsenical
keratosis, but vacuolization of the prickle cells is usually not so pronounced.
The neoplastic process may remain intradermal, but sometimes an infiltrating
squamous-cell epithelioma with metastases develops (in about 20 per cent of
the cases). Fraser (1928)* pointed out that the cellular changes are characteristic
of malignancy from the beginning; therefore the condition has to be classified,
not as a "precancerous" dermatosis, but as a real carcinoma, but without
infiltrating properties: an intradermal cancer of the squamous-cell type. Wise
(discussion to Fraser, 1928), Highman (ibid.,) and Ebert and Otsuka (1943) agree
with Fraser.
The question whether Bowen's disease is a strict entity was always a contro-
versial subject, especially whether a sharp line can be drawn against multiple
superficial epitheliomas. Bosellini (1928) denied this. Anderson held the view
that both conditions bear relationship to each other, their simultaneous occurrence
in some cases testifying this view. Wise (1920), Eliascheff (cit. Barber, 1928),
Montgomery (1929, 1935 and 1941), and Allington (discussion to Alderson,
1935) maintain that Bowen's disease is an entity and can be differentiated from
multiple superficial epitheliomas. But Montgomery admits that both conditions
are found occasionally associated, and that either can be associated with the
ordinary arsenical type ofepithelioma.
Wise (1928) and Fraser think that a definite diagnosis of Bowen's disease
cannot be made on clinical evidence but only by histological examination;
Montgomery andWVaisman(1941),ontheotherhand, state thatthesamehistological
structure is found also in other precancerous dermatoses. Montgomery (dis-
cussion to Goeckerman and Wilhelm, 1940) emphasized especially the fact that
malignant dyskeratosis simulating Bowen's disease is a characteristic feature of
the arsenical type of epithelioma. It is a matter of fact that almost no case
presented during the last years in a dermatological society has escaped doubts
about correct diagnosis (see Schoff, discussion to Alderson, 1935; Montgomery
about case 74; Ebert and Otsuka (1943, discussion); and the frequent use of
ill-defined terms such as "Bowenoid" or "Bowen-like" indicates the lack
of evidence in that matter.
Anderson (1932), having observed a case of Bowen's disease with a history of
arsenic, arsenic present in the urine, and keratoses of palms and soles (case 74),
* See also Lane, discussion to Ormsby and Mitchell, 1925.
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expressed the opinion that this condition as well as multiple superficial epithe-
liomas are the result of this poison. Fraser (1927 and 1928) reported a similar
incidence.
But H. Montgomery (1935) did not agree; in his five cases of Bowen's
disease neither had arsenic been administered nor were keratoses or pigmentation
present. He explains Anderson's case as an epithelioma of the arsenical type
simulating the clinical picture of Bowen's disease.
R. M. Montgomery (1942) reported a case of Bowen's disease verified by
autopsy in which arsenic was taken, with keratoses of fingers and toes (case 129).
Among the cases in Table I in only five the strict diagnosis ofBowen's disease
was made by one or another observer (cases 55, 74, 103, 129 and 133); in three
of them keratoses were present; in two association with multiple superficial
epitheliomas; in one of these also with keratoseogen cancer and two cancers
of mucous membranes. Besides, in seven incidences (67, 85, 109, 110, 121, 125
and 134) a "Bowen-like" or "Bowenoid" appearance is noted.
6. Extramammillary Paget's disease.
This affection, mostly localized on the genitals, seems to be very similar to, or
identical with Bowen's disease (Fraser, 1928; Highman, discussion to Fraser,
1928; and Montgomery, 1929). The relations to arsenic are not clear, but may
be the same as in Bowen's disease.
7. Arsenical cancer in other orqans than the skin.
In some instances arsenical cancer of the skin is associated with cancer in
other organs.
Thus one of Hutchinson's (1888) original cases died of cancer of the stomach
(case 5). In one of Ullmann's cases (case 33), of Hutchinson type, a cancer of
the tongue and later a cancer of the oral mucosa developed. It mnay be the
same case which was mentioned by Mayer (1933). Franseen and Taylor (1934)
refer to a case of keratoseogen cancer of the skin with a suspicion of associated
cancer oesophagi (case 88).
Associated with multiple superficial epitheliomas and with typical keratoses
a canceruterioccurred in the case ofMacCormac (1933a, b, case 76); withmultiple
epitheliomas and a squamous-cell epithelioma of the groin and a carcinoma of
the tongue in case 123 (Anderson, discussion to Goeckerman and Wilhelm, 1940).
In a case of Montgomery (1935), with association of keratotic epitheliomas
and numerous superficial epitheliomas (case 103) an intra-urethral epithelioma
developed and later a bronchial carcinoma of "arsenical type."
Goeckerman and Wilhelm (1940) observed a papilloma of ureter and bladder
in a case with keratosis of palms and soles and Bowen-like keratotic lesions on
the trunk (case 122). In the discussion to Montgomery and Waisman (1941),
Anderson mentions one case of Fraser and Fox and another of Goldman and
Tauber, both with papilloma of the bladder. Barney (1944) reported a cancer
ofthe oesophagus in a patient with keratoses and multiple superficial epitheliomas
beginning in a patch ofpsoriasis (case 138).
It may be assumed that these localizations on the mucous membranes were
also due to arsenic; several authors have made this suggestion (Ullmann, 1922;
GoeckermanandWilhelm, 1940; Montgomery, ibid., discussion; Anderson, ibid.),
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but it is not exactly proved; a mere coincidence cannot be excluded. Arsenic
never was identified in these growths until now.
In some cases after administration of arsenic, cancers in different organs
occurred without cutaneous cancer but with arsenical keratoses; thus a case
of cancer of the breast published by Dubreuilh (case 22). Franseen and Taylor
observed a cancer of the pancreas in a patient with typical keratoses (case 93).
In other cases after use of arsenic extracutaneous cancers occurred without
keratoses or other signs of chronic arsenicism; so in the cases of Milian (cancer
of the breast, case 70), and Semon (1945) (case 142, cancer of the bronchi). The
possibility of a mere coincidence of ingestion of arsenic and development of
cancer is here of course much greater.
The case of Rosen (discussion to Montgomery, 1935, case 108) concerning
epithelioma of the mouth after anti-syphilitic treatment with arsphenamines
is already mentioned.
8. Combination of types.
Frequently all epitheliomatous lesions in a patient belong to the same type
of arsenical cancer, e.g. several growths of the Hutchinson type. But in many
other cases two or more different types are associated, as keratoseogen cancer
with multiple superficial epitheliomas or with Bowen's disease. In some cases
the keratotic cancer develops earlier (as in cases 103 and 128); sometimes the
superficial epitheliomatosis (case 113). Lesions of the same type in a patient
may develop in a different manner, e.g. one superficial lesion as a basal-cell
epithelioma and the other as a squamous one. Further, there may arise addi-
tional cancers in other organs than the skin. So not seldom a very polymorphous
picture is produced not seen in other kinds of growth; as in the case of Guggen-
heim (1933, case 78), one cancroid, one basal-cell carcinoma and multiple atypical
lesions with Bowen-like changes were combined with verruca seborrhoeica;
another example is the case of Montgomery (1935, case 103, Table I).
9. Frequency of the different types of medicinal arsenical cancer.
It is impossible to group every one of all the 143 cases of Table I in the
different typesmentionedabove asthe data arenotalways sufficient; andbesides,
there are a number of cases presented in dermatological societies in which the
experts did not agree in the special diagnosis. But in about 136 incidences a
classification seems possible.
The total number of cases of the keratoseogen type may be assumed as 69.
Fifty-one cases belong apparently to the simple uncombined "Hutchinson
type"; in 36 of them the origin of the malignancy on a keratosis is definitely
noted (cases 1, 2, 3, 4, 6, 8, 10, 12, 13, 14, 15, 16, 17, 18, 20, 21, 25, 26, 27, 29,
34, 36, 37, 42, 47, 57, 59, 60, 84, 87, 90, 92, 102, 112, 130 and 143); in the
remaining 15 cases it can be assumed (cases 9, 19, 35, 40, 41, 46, 51, 56, 58, 62,
64, 71, 91, 94 and 126).
In 3 cases the Hutchinson type was associated with extra-cutaneous cancet
(5, 34 and 88).
In 13 cases there was a combination with multiple superficial epitheliomas
or with Bowen's disease (cases 11, 23, 49, 85, 104, 106, 107, 109, 111, 113, 116,
127 and 128); in 2 cases with multiple superficial epitheliomas and with extra-
cutaneous cancer (103 and 123). 67 cases mnay be counted as multiple superficial
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epitheliomas including Bowen's disease: 50 of them were uncombined cases
(28, 30, 44, 45, 50, 52, 55, 64, 65, 66, 67, 68, 72, 73, 74, 75, 77, 78, 79, 80, 81, 83,
86, 89, 95, 96, 97, 98, 99, 100, 101, 110, 115, 117, 118, 120, 121, 124, 125, 129,
131, 132, 133, 134, 135, 136, 137, 139, 140 and 141); in 13 cases they were
associated with the Hutchinson type (see above); in 1 case with extra-
cutaneous cancer (case 75); in 2 cases with the Hutchinson type and with
extracutaneous cancer (see above); in another case one of the multiple lesions
hadarisenina patch ofpsoriasis and was associated with cancer ofthe oesophagus
(see below). At the utmost five of these 67 incidences can be classified as cases
of Bowen's disease.
Origin of growth in a patch of psoriasis is noted in 7 cases (7, 23, 32, 39, 43,
46 and 138); in case 138 it was multiple superficial epitheliomatosis originating
in a patch ofpsoriasis; later a cancer ofthe oesophagus developed.
Special cases of -growths of the skin are: one incidence of fibrosarcoma
(case 53) and one of a melanosarcoma (?) followed by an epithelioma of the
cheek (case 69).
Thenumberofcases ofextracutaneous arsenical cancer is 13. In 6ofthesethe
skin was not affected (cases 22, 70, 93, 108, 122 and 142); in 7 there were also
lesions of the skin (see above).
It is hardly worth while to calculate the percentages of the various types, as
they depend also upon the interest the different forms have found at different
times. Thus before 1931, of39 incidences ofthe then modern keratoseogen type,
only 7 of the then nearly overlooked multiple superficial type, Bowen's disease
aid their combinations with the keratoseogen type were reported. Since 1931
the interest switched over to the latter forms and the ratio of the published
cases changed to 15: 57. Of all cases of epithelioma arising fromni a psoriatic
lesion all but one were reported before 1925.
10. Multiplicity of medicinal arsenical cancer.
Hutchinson himself emphasized that in arsenical cancer frequently several
(primary) growths are present. Pye-Smith (1913b) in his collection of 29 cases
found multiplicity of the lesions in fully half of all incidences. In Kennaway's
table (1925) there are 75 tumnours in 38 patients, giving an average of nearly
two tumours in each patient, and besides, two patients had numerous lesions.
Now that many cases of the multiple superficial type have been published,
the multiplicity appears to be even more pronounced. The calculation of the
cases in Table I shows:
Multiple superf. and
Plain keratoseogen Bowen cases, plain All cases. cases. and combined with
other types.
One lesion . . . 24 44.4% . 3 4-5% . 41- 28.7%
Twolesions . . . 10 18.5% . 3- 4.5%/ . 17- 11.9%
Three lesions. . . 6-- 11.1% . 6 9.0% . 12= 8.4%
Several(4-6)lesions . 13 24.1% . 23- 34.3% . 38= 26.6%
Numerous (10 or more)
lesions . . . 1- 1.9% . 32= 47.8% . 35 24-6%
S 54= 100-0% . 67=100.0% . 143= 100-2%
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It must be kept in mind that multiplicity of lesions is quite frequent also in
non-arsenical cutaneous epithelioma. In a review of 3000 cases of-malignant
tumours Owen (1921) found 143 (4.7 per cent) of multiple primary growths and
not less than 113 of them involved the skin only. And Schreiner and Wehr
(1934) report that the most common primary multiple tumour is the basal cell
epithelioma of the skin, the squamous-cell epithelioma of the skin being the
next in frequency. Hueper (1942) estimates that multiplicity in non-arsenical
cutaneous cancer is only 5 per cent.
It is evident that in the simple keratoseogen cases the average number of
growths is slightly over two; whereas in the multiple superficial cases with
their various combinations more than one-third shows more than one lesion and
more than one-half "numerous " or "several" lesions.
11. Distribution of medicinal arsenical cancer.
Hutchinson (1887 and 1888) laid stress on the frequency of location of the
malignancies on the hands and feet. Wile (1912) stated a predilection for sites
of frequent physiological or other trauma, in contrast to other cutaneous epithe-
liomas in which the face is the most common seat of disease. Following McCoy
(1920) 37.7 per cent of all cancers of the skin occur on the face, hands and
neck, all exposed to solar light. Kennaway in 1925 gave a review ofthe distribu-
tion in 38 cases published until this time, mostly of medicinal origin, including
the cases collected in 1913 by Pye-Smith. He confirmed the "well-known
tendency of arsenic to affect the fingers and toes" in contrast to cancers in
tar, pitch and shale oil workers, showing an outspoken predilection for scrotum,
head and neck. Among 75 arsenical growths in 38 patients:
46 per cent were located on fingers, leg, foot, toes and trunk.
23 per cent on arm and hand.
23 per cent on scrotum, penis, head, face, neck, eye and eyelid.
8 per cent on other parts.
Kennaway criticized the assertion of Bayet and Slosse (1919a, b) that the
scrotum and its neighbourhood are sites of predilection for arsenical cancer
this opinion was based on statistics, omitting the so frequent localization on
the hands.
Haagensen (1931), comparing the distribution of therapeutic arsenical cancer
with occupational cancer, reported 4 new cases of the former with multiple
lesions of the hands, arms, legs and trunk, but sparing the face and the scrotum
(cases 62, 63, 64 and 65).
Since then many cases ofmultiple superficial epitheliomas have been added-
partly pure cases, partly combined with other forms; these cases differ in their
distribution essentially from those in the HutchinSon keratoseogen type. There-
fore in Table II the cases of Table I are divided into several groups.
Table II confirms the preference of the keratoseogen Hutchinson type for
the distal parts of the extremities, as nearly 85 per cent of the cases show one or
more localizations on fingers, hands, toes and feet, and relatively few on other
regions. In contrast more than 92 per cent of the multiple superficial cases
pesented lesions on the trunk (the cases with distribution "all over the bodvy"
included), and frequently also on the proximal parts of the extremities and in
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more than one-third of the incidences on head and neck. The combined cases
show a combination of both sites ofpredilection. Localization in the genito-anal
region is relatively uncommon in both types. In the rare cases of epitheliomas
originating from patches of psoriasis nearly always the more proximal parts of
the extremities and the genito-anal region were affected.
12. Chronological course of medicinal arsenical cancer.*
The time elapsing from starting the arsenical drug until the beginning of
epitheliomatous growth lasts regularly many years hut varies within wide limits:
3 years in case 130 and 40 years in case 74, average being 18*1 years. Even
after the cessation of ingestion of arsenic there may be an interval of many
years, as 18 years in case 15. There is no marked difference in the duration of
this "latent period" between the different forms: in the Hutchinson type the
average duration is 18.8 years, in multiple superficial and Bowen's type 17.8
years, in the combined forms 19.7 years.
In the cases with keratoses, especially in the Hutchinson type and in the
comnbined type cases, this latent period may be divided into two stages, the first
being the interval between starting with arsenical drugs and the first ap-
pearance of the characteristic keratoses; this prekeratotic stage, noted in 19
cases, lasted from one yeart (in case 138) to 20 years (in case 104), with an
average of 8.8 years (see above). The second stage is the time between
appearance of the keratosis and the onset of epitheliomnatous growth; this
keratotic or precancerous stage, noted in only 11 cases, varies from one
year (cases 4 and 29) up to 23 years (case 35) with an average of 9.6 years.
13. Age at onset of medicinal arsenical cancer.
In spite of the usual long duration of the prodromal period the age when the
epitheliomas appear is relatively low--lower than in the common non-arsenical
cutaneous cancer. This starts only seldom before the fortieth year of life, the
average age being about 60 years (according to Pack and LeFevre (1930), 58
years for the squamous type and 61 years for the basal cell type). The earlier
development of arsenical cancer already recognized by Hutchinson (1887 and
1888) was confirmed by all authors. Pye-Smith (1913a, b) stated that in one-
quarter ofthe cases the patients did not exceed 35 years.
In calculating the age at onset of neoplastic growth in the cases of Table I
again the difficulty arises that in a great number of cases accurate dates are
missing. Among 115 cases (80 males and 35 females) the age of which is noted,
the start ofneoplastic growth can be fixed approximately (see Table III). About
one-third of all cases were not older than 40 years, and more than 60 per cent
not older than 50 years. Remarkable is the considerable number of females
between 20 and 30 years.
In one case (" case 2" of Oliver and Finnerud (1928), not included in Table
I on account ofthe absence of other details) the cancer appeared in a boy of 11
years.
* Duration of exposure to arsenic, see above.
t Appel (discussion to Lane, 1939) reports that in one of his cases arsenical keratoses developed
after only 3 weeks' use of arsenic, and Montgomery (1935) has seen keratoses one month after
starting the drug.
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IX. Histology of Arsenical Cancer.
Both main types of skin cancer are observed in arsenical malignancy:
1. The squamous-cell epithelioma = prickle cell ep. - spinocellular
ep. -= pearl forming ep. -epidermoid carcinoma, differentiating
into all the Malpighian layers; it is marked by a tendency to
cornification (" horny pearls" or "cell nests ") and a higher degree of
malignancy (metastases in lymph-nodes); it is the usual form in arsenical
epitheliomas arising on keratoses.
2. The basal cell epithelioma of Krompecher = basilioma = rodent
ulcer type, starting from the basal layer ofthe epidermis, with no tendency
to cornify and comparatively benign course (no tendency to metastases),
although it consists of younger and less differentiated cells than the
squamous type. It is the most frequent form in multiple superficial
epitheliomas.
There are also mixed forms and transitions from the basal-celled to the
squamous-celled type. Besides, both types of epithelioma may occur in the
same patient.
For the histology of Bowen's disease and extramammillary Paget's disease
see above.
Among 81 cases in Table I with cutaneous tumours in which the result of
histological examination is noted, at least 44 were of the squamous type and at
least 24 were basal-celled; one was a mixed form. In 10 cases squamous-cell
tumours as well as basal-cell tumours were present. Only in one case (129)
the growths were microscopically exactly identified as Bowen's disease. In
one case (case 53) a fibrosarcoma and in one case (case 69) a melanotic sarcoma
is noted.
X. Chemistry and Histochemistry in Arsenical Cancer.
Arsenic after ingestion for a long time is said to be deposited in the organs,
especially in the skin and its appendages (sweat glands, sebaceous glands,
hair follicles, hair and nails). Partly it is excreted-very slowly-by these
glands (see Cornbleeth, discussion to Montgomery and Waisman, 1941) and in
the urine. For chemical investigation in the living are available: urine, blood,
spinal fluid, hair, nails and excised samples of the normal and pathological skin.
The methods of chemical examination are based on the classic method of
Marsh. Now mostly used is the electrolytic technique of Gutzeit (1879) or of
Osterberg (1928). Table IV gives the results of the authors in cases of arsenical
epitheliomas in the urine.
The value of such investigations of the urine for the diagnosis and for the
clearing up of the pathogenesis is by no means as high as should beexpected. It
must be kept in mind that arsenic in small amounts is apparently a normal
constituent of the body, depending on environmental conditions, as water, food
and occupation (Heffter and Keeser, 1927; Rost, 1931).
Thomsen (1905 cit. Schwarz, 1932) was the first to detect arsenic in the normal
urine. Billeter and Marfurt (1923) found 0.00056 mg. per cent and 0-0104 mg. in
the daily quantity; Althausen and Gunther (1929) 0.08 and 0-16 mg. per cent;
Throne and Myers (1935) 0-00104 nig. per cent; they think an amount of over
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0'03 mg. per cent of dried substance to be pathological. Wuehrer (1937) found
0.005-0.095 mg. per cent in normal urine. In the urine of (healthy) workers
with arsenicals Schwarz (1932) detected amounts up to 0.82, and Wuehrer in
cases ofchronic arsenicism (without epitheliomas) 0-245-1 110 mg. per cent 2OP3.
So practically all quantities found in the urine of patients bearing arsenical
epitheliomas (Table IV) are within the limits sometimes contained in the urine
of apparently normal individuals.
It may be mentioned that after ingestion of arsenic the urine contains arsenic
partly as an organic compound (Salkowski, 1908).
Some authors report determinations of arsenic in blood (Cannon, discussion
to Montgomery 1935, and Montgomery, 1942) but no exact quantities are
given in cases of arsenical cancer.
Still less successful than the examination of the urine proved the investigation
ofhamir and nails in cases of arsenical growths. Caspar (1860) first described
the presence of arsenic in the hair of a patient in whom arsenical poisoning
was suspected. Since then many determinations in the hair were made
(Schwarz, 1932; Tost, 1931; and Wuehrer, 1937). The values in the hair of
normal persons lie between 0 and 0.18 mg. per cent (Myers and Cornwall, 1925;
Billeter and Marfurt, 1923; Althausen and Gunther, 1929; Wuehrer, 1937),
whereas after ingestion of arsenic and in (healthy) workers with arsenical
insecticides amounts of 0.245, 1.110, 5.0 and even 160 mg. per cent (Schwarz
and Deckert, 1943) were reported. It seems strange that investigation in three
cases of arsenical cancer (Montgomery, 1935, cases 96, 97 and 98 of Table I)
did not reveal any arsenic in the hair.
In the nails where normal amounts of 0.0172 mg. per cent were stated by
Billeter and Marfurt (1923), Hamilton (1921, case 36) found only a trace.
In normal skin Billeter and Marfurt (1923) detected 0-0097 mg. per cent, and
Oppenheim (1931) in the scales of normal skin 0*0026 mg. per cent. The
examination of the keratoses, growths and normal skin in cases of arsenical
cancer has given repeatedly negative results; as in the incidences 79, 101, 102
and 120 of Table I; in others amounts up to 8.6 mg. per cent (case 104) and
even 430 mg. per cent (case 127) were recorded (Table V).
The results of chemical determination are disappointing on the whole. The
main cause may be that-except for urine-usually only very small samples of
tissue are available. It seems that the methods of determining arsenic in such
small quantities are still unreliable. For this reason the histo-chemical
method is preferred bythe majorityofauthors. This"hydrogen sulphide method"
has been worked out by Justus (1905), following a proposal of Carlson; the
arsenic ofthe tissues is transformed to arsenictrisulphideAs2S3, which can be recog-
nized microscopically as yellow-brown to greenish-yellow crystals of high
refractivity, nearly always of uniform size. The original technique has been
modified by Bruenauer (1921) and Osborne (1925, 1928 and 1932). Osborne's
technique is now mostly used. As a microscopical method of course it cannot
give real quantitative values, but it is very sensitive, requires a minimal quantity
of material and permits a location of the arsenical deposit. The method is
supported by a series ofauthors: Montgomery (1935), Montgomery and Waisman
(1941), and O'Leary (discussion to Waugh and Scull, 1935). But it has not
escaped criticism. Muir and Tannenholz (1933) objected, stating that the crystals
were in reality sulphides of albumin. Other authors are also critical concerning
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the proof of arsenic by the histo-chemical method: Oppenheim and Fantl
(1934), Becker (discussion to Waugh and Scull, 1935), and Nomland (ibid.). In
any case the method requires fully experienced qualified investigators.
Bruenauer and Osborne obtained always negative results in the skin of
normal persons and positive in arsenical keratoses.
Anderson (1932, case 69) and Goeckerman and Wilhelm (1940, case 114)
reported positive results with Osborne's method. But the most extensive use
of examining normal and pathological skin of the patients by chemical and
histochemical methods was made by Montgomery (1935, 1941) (Table V).
Montgomery himself emphasizes that arsenic in pathological amounts can
be found by Osterberg's method in cases of various types of dermatoses without
there being any clinical evidence of arsenic, as keratoses or pigmentation. On
the other hand, neither he nor Osborne was able to demonstrate arsenic in the
skin of certain patients who had got arsenic for some time, even in some cases
with arsenical keratoses or typical arsenical cancer. So the mere demonstration
of arsenic by chemical or histochemical methods does not prove that the drug
is an etiological factor in a given case; and its absence does not exclude arsenic
as a causative factor. O'Leary (discussion to Waugh and Scull, 1935) has
confirmed these observations.
Cannon (discussion to Montgomery, 1935) may be right in saying that it is
necessary to learn more about the significance of arsenic in normal persons.
Guthmann (1938) reported that he had found in the venous blood of normal
women 0.01-0-06 mg. per cent, with considerable variations corresponding to the
menstrual cycle, and still higher amounts up to 0.24 mg. per cent in pregnancy.
In cancers of different origins he found quantities of 6-7 mg. per cent, together
with anincreaseinthe venous bloodup to 41 times thenormalvalue. Hesuggests
a close general connection of arsenic with different proliferation of cells. But
his values are so astonishing and in such apparent contradiction to the results
of other authors that confirmation would be necessary (see p. 229, Pathogenesis).
XI. Prognosis. of Arsenical Cancer.
As with cutaneous cancers in general, arsenical epitheliomas of the skin are
slowly growing neoplasms with a relatively low grade of malignancy, the micro-
scopically basal-ceolled forms giving a better prognosis than the squamous ones.
Besides, there are obvious differences between the different clinical types.
The keratoseogen cancers of the Hutchinson type-nearly always squamous
forms-although often growing very tardily at first, give the most unfavourable
ultimate prospect; especially the cases originating on the fingers. They lead
eventually to metastases in the regional nodes and in the internal organs, to
emaciation and death; the multiplicity of lesions is another aggravating factor.
Such tumours localized on other sites seem to have a somewhat less unfavourable
course.
Much better is the prognosis in superficial epitheliomas and in Bowen's
disease; but there are also differences. The most favourable are the cases of
true superficial "benign " epitheliomatosis showing the histological picture
of basal-celled epitheliomas, and often without any sign of keratosis or
pigmentation. They cannot be called real cancers, but occasionally they
become malignant (e.g. case 139, discussion to Glen, 1945), or they are associated
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with other malignant forms of epithelioma. Less favourable are the cases of
superficial epitheliomas with marked keratoses (Montgomery's "epithelioma of
the arsenical type "), frequently showing the histological picture ofsquamous-cell
epithelioma; they are usually not so malignant as the keratoseogen forms, and
Montgomery and Waisman (1941) suggest that the clinical course is frequently
not so bad as the histological picture would suggest, but nevertheless they often
lead to invasive growth, metastases and death.
In Bowen's disease (see p. 205) the lesions may be constant for many years,
although the microscopical picture is like squamous cancer. Approximately
20 per cent eventually develop into a penetrating form of cancer.
Death is noted in 17 cases of Table I, but no doubt the number of fatal cases
is in reality far greater.
XII. Treatment of M_edicinal Arsenical Cancer.
There is general agreement that the main task in therapy is prophylaxis.
That means, in medicinal arsenical cancer, to confine the use of this powerful
drug to the cases of necessity. Arsenic seems to be dispensable as a tonic and
as a preventive for bromide eruption in epilepsy, etc. (its efficiency for that is
even doubtful, see Wigley, discussion to Russell and Klaber, 1945). That
applies especially to the treatment of psoriasis, as patients suffering from this
disease are apparently more susceptible to the different kinds of arsenical epithe-
lioma. The question was specially discussed in connection with Anderson's
paper (1937). Some authors (Ayres, discussion to Anderson, 1937; Nether-
ton, discussion to Barney, 1944) suggest that the benefit obtained by arsenic in
psoriasis does not justify the risk of administering it, or only in exceptional
cases. Caskey (discussion to Anderson, 1937) declared he never mentions
arsenic to his students or physicians without condemning it. Others (e.g.
Jacobsen, discussion to Anderson, 1937) do not go so far; for arsenic is doubtless
very effective in many cases of psoriasis-testified by the very histories of some
patients of Table I (see cases 1, 23, 24, 38, 43, 120 and 130); and it must be
considered thatincomparisonwiththe highfrequency ofpsoriasis and the general
use ofarsenic for its treatment the development ofarsenical cancer is quite a rare
event. In thetherapy oflichenplanus andofdermatitisherpetiformis also arsenic
cannot be sparedeasily. Halloran (discussion toAnderson, 1937) declareditwould
be a mistake to develop a tear complex as to the use of arsenic as a drug. But
certainly there should be legislation to prevent or curtailthegeneral use ofarsenic
in patent medicines, and it should not be permitted that a patient can get the
drug continuously without a new prescription. Repeatedly it was claimed in the
discussions that the prescription must have the remark, " Not to be refilled."
It is equally necessary to instruct students about the danger of arsenical
medication, and the indispensability of a regular control of patients treated
with arsenic. The use of arsenical paste for the treatment of cancer should
be abandoned, even although it has proved in some cases to be successful (see
picture in Sutton, 1939, p. 729).
Ullmann and Galloway (discussion to Pye-Smith, 1913a) sounded a note of
warning that the use of arsphenamine-in large quantities might also be followed
by malignant epithelial lesions. But experience has shown that there is not
sufficient reason to restrict such a valuable drug in the treatment of syphilis, as
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the development of malignancy after its use is very exceptional (see p. 196),
and such patients are as a rule under medical supervision. Only in cases
of syphilitic affection of the mouth, especially leucoplakia, a certain reserve
may be recommended (Rosen, discussion to Montgomery, 1935).
As soon as signs of chronic arsenicism (pigmentation, keratosis, etc.) begin
to appear, the medication with arsenic has to be stopped at once. The use of
sodiumn thiosulphate was recommended: 5-10 c.c. of freshly prepared 10 per
cent solution intravenously every third day or orally 0.5 g. in enterically coated
tablets. Ravaut (1920) and Dennie and McBride (1924) have introduced this
treatment. It is supposed that this salt converts arsenic in the body into the
insoluble harmless sulphide (see Throne and Myers, 1935). Some authors
(Ayres and Anderson, 1938) believe that it increases the excretion of the
poison. Many authors support this treatment: Althausen and Gunther, 1929;
Throne and Myers, 1935; Greenwood (discussion to Lane, 1939). But
new investigations have shaken its theoretical basis (Editorial, 1942;
Abramowitz, Mattice and Bottvinck, 1944). Appel (discussion to Lane, 1939)
recommends the external local use of sodium thiosulphate in the form of fairly
concentrated soaks. Also, soothing ointments (hydrous wool fat andpetrolatum)
or keratolytic ointments (with salicylic acid) may be applied for removing the
keratoses. Franseen and Taylor (1934) recommend prophylactic destruction of
the keratoses already in the pre-cancerous period. But it must be kept in mind
that any irritation, mechanical or chemical, must be avoided (see p. 229, Patho-
genesis). Of course regular medical supervision is necessary.
If a case of keratosis is developing signs of malignancy, radical measures
have to be taken at once; they consist either of surgical removal (excision), or
destruction by one or the other forms of cautery. In cancerous lesions of the
fingers, and in extensive lesions of other parts of the extremities, amputation is
advisable. It has been recommended in all cases of squamous cancer to remove
the regional nodes too (Franseen and Taylor, 1934).
The more conservative methods of treatment such as radiotherapy (X-rays,
radium) have proved insufficient, and even contra-indicated in keratoseogen
arsenical lesions; recurrences were observed very often (Montgomery and
Waisman, 1941). Some authors recommend radiotherapy as an after-treatment
after surgical removal; but others (Galloway, discussion to Pye-Smith,
1913a) think that radiotherapy should be avoided entirely in the treatment of
arsenical cancer.
'
For the treatment of multiple superficial epitheliomas and Bowen's disease
it wasthoughtthat less radical procedures are justified, such asthe useof X-rays,
radium, ultraviolet irradiation (Ayres, 1934), or "Grenzstrahlen" (Kindler,
discussion to Glen, 1945). But already Graham Little (1923) had noted the
marked radio-resistance of these lesions, and other authors have confirmed this
observation (Lane, discussion to Ormsby and Mitchell, 1925; Anderson, 1932;
Glen, 1945; Dowling, discussion to Glen, 1945). Graham Little recom-
mended freezing with carbon dioxide snow, already proposed by Galloway
(discussion to Pye-Smith, 1913a); Schamberg (discussion to Pfahler, 1927)
and Crawford (ibid.), electro-desiccation; Rodgers (1941) used cauterization with
silver nitrate; Pusey (discussion to Ormsby and Mitchell, 1925), painting with
nitrate ofmercury (Weber, ibid.). But most ofthe experts now advise complete excision also for this kind of epithelioma, if necessary with skin grafting (Lane,
15
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discussion to Ormsby and Mitchell, 1925; Michelson, discussion to Fraser, 1928;
Montgomery, 1929; Glen, 1945; Dowling, discussion to Glen, 1945). Of
course there may be difficulties in cases with numerous lesions. Ayres (1934)
recommended after-treatment with sodium thiosulphate against further develop-
ment of epitheliomas.
Of course, periodical re-examination of the skin is essential.
B. ARSENICAL CANCER CAUSED BY DRINKING-WATER.
As early as in 1809 Lambe (Eggers, 1932) expressed the belief that arsenic
in potable water may be the cause of malignant disease.
One of the most impressive examples of an endemic occurrence of chronic
arsenicism is the so-called Disease of Reichenstein (" Reichensteiner Krankheit ").
Reichenstein is a small town in the county of Glatz, Silesia, where for many
centuries gold was produced from gold-containing arsenical ores: arsenopyrite
(= arsenkies, mispickel FeAsS) and lollingite (- arsenikalkies _ arseneisen
FeAs2 respectively Fe2As3 and Fe2Ass). With the old methods of smelting large
quantities of arsenical fumes escaped, were precipitated with the rain and thus
reached the underground water, the brooks and the drinking-water. In one of
the brooks (" Giftbach " poisonous brook) 1-22 mg. per cent arsenic was
found; in samples ofthe mud up to 500 mg. per cent. Later the gold production
was dropped and only arsenic was produced. For centuries the high incidence
of serious diseases in that town was known. But not until 1898 was the nature
of this disease recognized as chronic arsenic poisoning, and described by Geyer.
The main symptoms were: troubles of the gastro-intestinal tract, ulcers in the
mouth, perforation of the nasal septum, paraesthesia, and especially melanosis
and keratotic warts on fingers and hands of the same appearance as in arsenical
poisoning. In some cases cancer developed. Geyer refers to the reports of
two local practitioners giving details ofthree cases ofthis kind, all with keratoses
of the hands and melanosis. It seems that such cases were very frequent in
Reichenstein; for Kathe (1937) was told by another doctor there that half of
his patients with "Reichenstein disease " had died with cancer. Unfortunately
written records are missing.
The "Reichenstein disease " has disappeared since the methods of smelting
have been changed, and particularly since the town was provided with a new
and adequate water supply in 1928, with an arsenic content of at the most
0.0015 mg. per cent (Geyer, 1940).
Another occurrence of endemic arsenical intoxication caused by drinking-
water is reported from the Argentine, province of Cordoba. In a wide area in
the south and east of this province, including the town of Bellville, such cases
have been observed by Goyenchea, by Ayerza and Arrillaga and others (Fer-
nandez, 1925; Bosco, 1925; Roffo and Correa, 1926; Alvarez and Ruiz, 1927;
Alvarez, 1928; Garcia and Ruiz, 1928; Alvarado, 1930; Seminario and
Alvarado, 1931; Roffo and Rosner, 1935; Trelles, 1937; Arguello, Cenget and
Tello, 1938; Arguello, Ferraris and Tello, 1938; Arguello, Tello and Marcola,
1942; Zinny and Vivaldo, 1942; Arguello and Tello, 1943). Thedrinking-wells of
Bellville have been found to contain an abnormally high amount of arsenic,
up to 0.28 and 0.45 mg. per cent; iodine and vanadium are also present in many
of these waters. Many cancers of the skin have been observed in Bellville,
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mostly in peasants. Arguello and co-workers alone give reports of 65 cases.
The clinical picture is in accordance with that of cancer caused by arsenical
drugs: keratoses ofthe palms and soles seem to be present in nearly all cases, as
in all 39 cases reported by Arguello, Cenget and Tello (1938); often melanosis-in
12 per cent of the cases in the mentioned paper. There is also a tendency to
multiplicity and a predilection for the limnbs, especially hands and feet, and a
relative rarity of localization on the head. Among their 39 cases Arguello and
his co-workers found multiplicity in 33*3 per cent; localization on the limbs in
38 per cent; on the trunk in 13 per cent; on the head in only 15 per cent;
in no case on the genitals. The corresponding percentages in non-arsenical
cutaneous cancer was found by the same authors to be: mnultiplicity in 5 per
cent, site on the limbs in 4 per cent, on the trunk in 2.5 per cent, on the head in
81*5 per cent, and on the genitalia in 5 per cent.
The majority of the epitheliomas were of the squamous cell type (51 per
cent); less frequently of the basal cell type (7.6 per cent). In a second paper
Arguello, Ferraris and Tello (1938) report 26 new incidences, including three
cases of Bowen's disease supporting Anderson's view that Bowen's disease is a
form of arsenical intoxication (see p. 205).
There are several wells in Europe with a very high content of arsenic, fre-
quently used for therapeutical purpose, as:
Guberquelle (Bosnie) . . . 0.6 nmg. per cent arsenic.
Levico (Tyrol) ... . -6 ,
Duerkheim (Palatinate) . . . 174 , .. ..
Roncegno (Tyrol) . . . . 4 26 ,
for comnparison:
Bellville in the Argentine . . . 0 28-0 45 mg. per cent arsenic.
"Giftbach," Reichenstein. .. . 22 mg. per cent arsenic.
In the Report of the Royal Commission on Arsenical Poisoning (1903) the
limit of arsenic for liquid food (and water) was set up as one-hundredth of a
grain of As20e per gallon = 0.015 mg. per cent. Nothing is known of a more
frequent occurrence of cancer in these localities either at the present time or in
the past.
Summarizing, it can be stated that cancer caused by the arsenic content of
drinkingwateris apparentlyidenticalwithmedicinalarsenical cancer. InCordoba
not only the keratoseogentype but also the multiple superficialtype and Bowen's
disease were observed; that they are not mentioned in Reichenstein is not
astonishing, as at that time these affections were not known. It seems that in
Reichenstein inelanosis was very frequent, and more pronounced than usual in
the medicinal cases; besides, perforation of the nasal septum is mentioned
as a frequent sign, not hitherto observed after ingestion of arsenic as a drug.
But these are minor differences.
C. OCCUPATIONAL ARSENICAL CANCER.
I. Arsenical Cancer in Miners and Smelters.
The first hint that arsenic may be the cause of dev-elopment of cancer in
man is to be found in the Pharmacologia of Dr. J. A. Ayrton Paris. Having
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practised in Penzance (Cornwall) from 1813-1817, he asserts that the smelting
works developing arsenical fumes in Cornwall and Wales occasionally cause in
the workers cancerous disease ofthe scrotum similar to that which affects chimney
sweeps. This remark of Paris, quoted over and over again, was criticized by
Butlin and by Kennaway.
Butlin (1892), making careful inquiries of the doctors in Camborne and
Hayle, failed to find the smallest evidence confirming the assertions of Paris;
the doctors practising there had never seen a case of scrotal cancer. A later
inquiry by Hulke (discussion to Lane, 1894) amongst the workers in the Cornwall
mines as to the occurrence ofcancers also had a negative result. These differences
could perhaps be explained by the fact that the method of smelting since Paris'
time had changed, producing now mainly tin and developing less arsenic fumes.
But that would not meet the objection pointed out by Kennaway (1943)
that the arsenical cancer prefers other locations, affecting the scrotum very
seldom. Out of 75 cases of arsenical cancer reported in the literature only 4
were localized there.
The question has been discussed as to whether the so-called "Schneeberger
Lungenkrebs" and the pulmonary cancers observed amongst the miners of
Joachirnsthal are due to arsenic. For centuries the high mortality rate amongst
the miners in Schneeberg and in other districts of the Saxonian Erzgebirge
(ore mountains), as Annaberg, etc., has been known. It was mentioned by
Agricola (1556) and in chronicles as due to "Bergkrankheit" (mountain
disease). But not until 1879 was the condition described by Haerting and Hesse
as cancer of the lungs. Arnstein (1913a, b) stated that they are real carci-
nonmas, not lymphosarcomas or endotheliomas, as was suggested by Wagner
and Weigert. Haerting and Hesse stated that 75 per cent of all deaths of the
miners was due to this affection-later statistics show 40-70 per cent (Arnstein,
1913a, b; Lange, 1935). The onset of the disease in this district occurred as a
rule after 20 years of working in the mines.
As other persons in this district were affected very rarely, this kind of cancer
must be in some way connected with the mining. Haerting and Hesse assumed
the cause of the disease to be irritation caused by inhaled arsenic with other
respiratory affections and a bad state of nutrition as predisposing factors. The
main ores in Schneeberg--besides sulphidic ones-are arsenides, as "Speiskobalt"
(tin white cobalt CoAs2), "Weissnickelkies" (white nickel NiAs2) and "Rot-
nickelkies" (arsenical nickel NiAs); these compounds are more soluble than
the compounds of arsenic and sulphur present in other cobalt pits. The bore-
dust of the mines contains up to 0.45 per cent As (Rostoski, Saupe and Schmorl,
1926), the dust in the pits 0.1 per cont. For the importance of arsenic in the
etiology of the Schneeberg cancer Saupe (1930) laid stress on the experimental
production of pulmonary malignancy by Fischer-Wasels (1929, see p. 228) and
Schmorl's (cit. Saupe, 1930) finding of two cases of lung cancer in the necropsies
of workers in the forges of Freiberg-Muldenhuetten, where now arsenic is pro-
duced from different ores. But Saupe himself (1930) was unable to detect more
instances of lung cancer in Freiberg, although sometimes signs of chronic
arsenicism were found. It may be remembered that-why, is not known-in
the last ten years cancer of the lungs, formerly rare, has become a quite frequent
disease.
Considering all facts arsenic can hardly be said to have an important etiological
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role in the Schneeberg cancer. No other signs of arsenicism are reported in
these patients, especially not keratoses. The localization of cancer in the lungs
is extremely rare in typical arsenical cancer: out of 143 medicinal arsenical
epitheliomas of Table I the lungs and the bronchi were affected only in two
cases (103 and 142). On the other hand, in the Schneeberg cases, although
eczematous changes occurred frequently, never a cancer of the skin has been
reported. Multiplicity of the tumours, so frequent in true arsenical cancer, is
usually missing in the Schneeberg malignancies (Hueck, 1939/40). The tests for
arsenic in urine, hair and nails gave negative or doubtffl results (Rostoski,
Saupe and Schmnorl, 1926), and so did the examination of the lungs (Pirchan and
Sickl, 1932, in Joachimsthal miners, and Ziel, 1935). Besides, pulmonary
cancer is not very frequent in other parts of the world where arsenic is
mined.
Other factors blamed for causing the Schneeberg cancer are: pneumoko-
niosis, chronic irritation by respiratory diseases, cobalt and hereditary suscepti-
bilitv.
Now the general view is that the main etiological factor is the presence in
the pits ofradioactive substances, the carcinogenic action of which is well known
(Ludewig and Lorenser, 1924). Also it was stated that in Joachimsthal, on
the southern side of the Erzgebirge, famous for its content of pitchblende and
radium. lung cancer is also found (Loewy, 1929; Sikl, 1930). In the
necropsies of the miners there between 1928 and 1.938 summarized by Peller
(1939), in about 50 per cent lung cancer was found. In contrast to that, in the
mines of Southern Sweden containing Speiskobalt, as in the Schneeberg mines,
pulmonary cancer is unknown.
Recently Lorenz (1944) arrived at the opinion that radioactivity cannot be
the sole cause of the pulmonary cancer of the miners, because similar doses of
X- or y-rays do not produce lung tumours in animals. He suggests some con-
tributory factors, including arsenic.
Although there is no basis to suppose that arsenical cancer is widespread in
miners and smelters, that does not deny that such cases occur occasionally.
Some cases are reported in the literature: the case of Anderson (1932, case 1
cf Table VI), concerning a man of 51 who as a boy had worked in a smelting
works in Mexico, and developed warty keratoses of palms and soles and multiple
benign superficial basal-celled epitheliomas; in the normal parts of the skin
arsenic was detected, and still more in the lesions. The patient knew the lesions
were due to arsenic. He stated that "everybody in the Mexican mines has
the same thing."
Another case was reported by Migayi (1935): after this man had worked for
ten years in a copper smeltery in Japan in which arsenic was produced,
keratotic changes appeared on the soles and palms, pigmentation of the skin, and
some years later a cancerous ulcer (squamous) developed on a keratosis.
A third case is that of Schaerrer (1934)-a worker mining or smelting
silver ores.
A fourth case was mentioned by Andrews (discussion to Goeckerman and
Wilhelm, 1940)-a miner in a copper mine, with typical keratoses and epithe-
liomas.
Also Bayet (1930) cites Rayer, who reported some cases of arsenical cancer
among workmen employed in the handling of arsenical ores.
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II. Arsenical Cancer in Factories.
1. Sheep dip factories.
Legge (1902) described, from a sheep dip factory in England, incidences of
irritation of the upper air passages combined with keratosis of the skin and
pigmentation as indicative of arsenic poisoning. Sheep dip is a compound of
arsenite of soda and free arsenious acid used for the treatment of mange in sheep.
The product is very dusty. Eve stated in 1910 that all workers at the factory
were deeply pigmented (O'Donovan, 1928).
Pye-Smith (1913b) in his table of 31 cases of arsenical cancer recorded two
until then unpublished incidences of cutaneous cancer in persons employed for
years in such a factory, observed by Eve and by Porter. These observations
were verified by later experience. Legge (1923, 1924) reported four similar
cases. O'Donovan, describing again Porter's and one of Legge's cases, gave a
review of the facts. Bridge (1926, 1930) mentioned three further incidences.
Legge (1934), repeating apparently three of the former observations, reported
another doubtful case. Merewether (1943) detected the incidence of fatal
pulmonary cancer in a sheep dip worker, and remarked that 3 similar cases
occurring in sheep dip workers had been notified since 1939. Currie (1947)
found columnar-celled adenocarcinoma in the lung and bronchial lymph glands
in case 15, Table VI. It is not noted whether these patients have shown any
signs of chronic arsenicism, especially keratoses. So this matter needs further
examination. This amounts to 13 cases of arsenical cancer in sheep dip workers
all observed in England (Table VI). Arsenicism in sheep dip workers has become
rare since the plants were remnodelled to render them as nearly dust-free as
possible.
2. Cancer caused by arsenical insecticides.
Chronic arsenicism has been observed in workers employed in the manu-
facture of arsenical insecticides. There are a great number of different prepara-
tions, -with trade-marks such as Emeraldgreen, Silesiagreen, Titaniagreen,
Urbangreen, Aresin, Esturmit, Vinuran, Grelit, Meritol, Nosprason, etc. Most
of them contain as the main compound aceto-acetate-arsenite of copper-
Schweinfurt-green Cu(C2H302)-+ 3Cu(AsO2)2; others, arsenite of copper;
Scheele's green CuHAs03; others calcium arsenate or lead arsenate. Schwartz
and Deckert (1943) found very large amounts of arsenic in the hair of these
workers, 74 to 160 rmg. per cent (see p. 212).
The arsenicism in these workers may lead to the development of cancer;
two incidences were published, one by Legge (1925) and by Bridge (1928),
another by Bridge (1939); the latter with a pulmonary cancer besides skin
mnanifestations (see Table VI).
These arsenical insecticides are especially used by gardeners, fruit fariaers
and vintagers for combating peronospora. They are used partly in the form of a
powder and partly as a spray. It is no wonder that chronic arsenicism has been
found also in such workers (.Doerle and Ziegler, 1930).* Hyperkeratosis of the
* Aschoff (1887-1899)was the first who brought attention to the high frequency of cutaneous
cancer in gardeners; this observation was confirmed by Young and Russell (1926), who stated that
in gardeners, nurserymen, seedsmen and domestic gardeners the percentage of death from cancer of
the face is 150 per cent in excess of the expected amount, deaths from cancer of the hands even 300
per cent. Exposure to sunlight, contamination with fertilizers (soot!) were held responsible; but
handling ofarsenical insecticides surely plays also a role.
220ARSENICAL CANCER
skin with multiple warts and melanosis are the most conspicuous symptoms
(Pein, 1938a,b). In some of such cases cancer ofthe skin developed (see Table
VI, cases 20-23). All four cases showed keratoses, two melanosis. But none
of them. presented the true Hutchinson type of skin cancer. The cases 21, 22
and 23 may be grouped as multiple superficial epitheliomas. Case 20 shows
an uncommon localization all over the face; it may belong to the type mentioned
by Cannon (discussion to Montgomery, 1935) (see p. 204).
Pein and Baurhenn (1943) believe that the high incidence of arsenicism in
wine-dressers in Germany is not really occupational, but is due to the con-
sumption of wine at home (" home-drink "). This may contain 0.1-0.2-0.5 mg.
per cent arsenic, i.e. up to 2-12 mg. daily.
3. Arsenical cancer caused by coal and its by-products.
Cancer of the scrotum in chimney sweeps is well known since its descrip-
tion by Pott (1775). Volkmann (1875) described occurrence of scrotal cancer
in workers with tar, paraffin and sobt. One year later Manouvrier in Lyons
(Bayet and Slosse, 1919) reportedthat intheworkers with coaland itsby-products
frequently a syndrome was observed which he supposed to be caused by a poison
and which he nanmed "l'intoxication houilliere"; but he was not able to find
out the responsible poison.
Pye-Smith in 1913 brought attention to the fact that pit-coal contains always
arsenicated iron-pyrites in various proportion, and that its derivatives, such as
soot, tar and pitch, contain still more of this poison. He pointed out that the
affections of the skin often seen in these workers (keratosis, melanosis, warts and
epithelioma) might be explained in that way, including the cancer of chimney-
sweeps, much more frequently found in England than on the Continent, where
wood coal was more commonly used.
Bayet and Slosse resumed these thoughts in 1919 with much emphasis. They
found arsenic not only in pit-coal and its by-products, but also in blood, hair
and urine of the majority of the workers engaged in making briquettes from
pitch. They suggested that the clinical picture ofthe " l'intoxication houilliere"
is identical with that of chronic arsenicism; melanosis, hyperkeratoses, troubles
of the digestive tract, bronchitis, ulceration of the nasal fossa and the occasional
occurrence of cutaneous cancer with special features; appearance at a relatively
early age, development on a keratosis (" verrue du brai "), frequent multiplicity,
frequent localization on the scrotum and its neighbourhood. Bayet asserted
that 70 per cent of the cases of both arsenical cancer and coal cancer had this
location. So Bayet and Slosse concluded: "Le cancer arsenical et le cancer
du goudron sont identiques."
This view, although accepted by some authors, as La Rossa (1925), has been
rejected by both German and English authorities:
1. Some kinds of coal and tar, although free or nearly free of arsenic,
cause also cancer in mice (Moeller, 1923; Daels, 1923; and Ross, cit.
Bayet, 1930).
2. Bayet and Slosse (1919) themselves mentioned that their theory is
urinable to explain the fact that the workers handling coal itself (les
"houilleurs ") are mostly not affected in contrast to the relatively high
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incidence in workers employed with the by-products, such as tar, soot,
pitch, etc. (Pye-Smith, 1913b).
3. The identity of the clinical pictures has been denied. The kera-
toses of the palms and soles so characteristic of chronic arsenicism are
not typical of cancer caused by the by-products of coal. It is true that
pigmentation is found in both conditions, but in pitchworkers it affects
mostly the bare parts of the body. But the main objection is that the
anatomical distribution is essentially different in pitch cancer and in
real arsenical cancer, as Kennaway (1925) has pointed out in a
special study. In contrast to the well-known predilection of arsenical
cancer of fingers and toes, only two out of 209 cancers were situated on
the fingers and none on the toes. Nearly one-half ofthe arsenical cancers
but only 4 per cent of the pitch and tar cancers were situated on the
fingers, hands, legs and trunk; on the other hand 83 per cent ofthe pitch
and tar cancers but only 23 per cent ofthe arsenic cancers occurred on the
head, neck and scrotum; so the special liability of the scrotum as the site
of the pitch and tar cancer is not seen in arsenical cancer. The statistics
of Bayet and Slosse were distorted by their procedure to exclude a priori
all localizations on the palms and soles. Besides, the multiplicity of
tumours is much more pronounced in the arsenical cases-75 cancers in
38 cases (the two cases of multiple cancers excluded), whereas in 123
persons with tar and pitch cancer only 144 tumours were recorded.
4. Finally, the theory of Bayet and Slosse has lost any basis by the
definite identification of the real carcinogenic comnponents of tar and
pitch by the work of Kennaway and Cook..
So the theory of Bayet and Slosse has to be abandoned.
4. Cancer of the bladder in aniline workers.
Bayet and Slosse (1919), Bayet (1930) and Hamilton (1921) have suggested
that the papillomatous and cancerous tumours ofthe bladder observed repeatedly
in workers with aniline dyes may be caused by arsenic. They based this con-
tention on the presence of arsenic as a contaminant in these dyes, the demon-
stration of arsenic in the urine (Wignall, 1920), and the possible similarity of
cutaneous manifestations in these workers with arsenical dermatitis.
But this view was opposed by many authors (Posner, 1904, 1905 and 1924;
Kennaway, 1925; UJllmann, Henry, 1930; Berenblum, 1932). Tumours of
the urinary tract have been observed in arsenic poisoning but are very rare
(see p. 206); the dye-workers suffering from cancer of the bladder present no
signs of chronic arsenicism. Kennaway has pointed out that it is not clear why
arsenic should cause cancer of the bladder in aniline workers, But cutaneous
cancer in the general population. However, the aniline dyes are now free of
arsenic, so that this poison can no longer be responsible for these bladder growths.
III. Comment on Occupational Arsenical Cancer.
In reviewing the observations in the literature in a critical way, a series of
suspected occupational arsenical cancers must be excluded. There is no evidence
whatsoever that arsenic is responsible for the pulmonary cancers of Schneeberg
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and Joachimsthal, for the malignancies in coal and pitch workers, and for the
bladder tumours in aniline workers. Only the occurrence in factories of sheep-
dip and of arsenical insecticides, in gardeners, farmers and vintagers and a few
incidences in miners and smelters (see above) really can be attributed to arsenic.
The total number of such cases recorded until now is, as Hueper (1942) mentions,
astonishingly small in comparison with the large number of persons exposed to
arsenic in industry. It may amount to about 25 cases.*
The clinical picture of these occupational cancers is on the whole the same as
in the more frequent and well-known medicinal cases. But there are some special
features in the occupational cases (Fassrainer, 1936).
(1) All reported cases concerned males-a not surprising fact.
(2) The period of exposure to arsenicals is very long in most cases, ranging
from 4 to 46 years, with an average of about 25 years (Table VI).
(3) Perforation ofthe nasal septum, a sign never mentioned in the therapeutic
cases is very frequent as a concomitant in workers in sheep-dip factories (Legge,
1934), as well as in workers producing arsenical insecticides (Bridge, 1928, 1939).
The reason why this symnptom has not been observed in the medicinal cases
may be found in the different route of exposure, the poison in the occupational
cases being inhaled as dust and so irritating the upper air passages. But in the
Reichenstein disease caused by drinking arsenic-contaminated water it is
mentioned also as a frequent sign (see p. 216). It may b)e that such perforations
occurred in some of the medicinal cases also, but escaped observation as they
make no deformity and often no trouble, so that many ofthe affected are ignorant
of this condition (Legge, 1934).
(4) Melanosis of the skin seems to be more frequent and more pronounced in
the occupational cases. Whereas pigmentation is mentioned in only 16.4 per
cent of the medicinal cases, it was present in at least 9 of 16 cases about which
detailed notes are given, i.e. in 56 per cent (see Table VI). Legge (1934) seems
to be inclined to ascribe this pigmentation of the skin to the working for years
in contact with arsenical dust. But it may be remembered that in endemic
arsenical cancer caused by drinking water (Reichenstein, Cordoba), pronounced
melanosis is an almost constant sign.
(5) Keratosis, especially keratosis of the palms and soles, seems to be as
frequent as in the therapeutic form. Among 16 cases described in detail keratoses
are noted in 13 instances-81 per cent.
(6) The distribution of the lesions does not show marked predilection for
the fingers, hands and feet as in the medicinal cases. This apparently is due to
the factthat in the occupational cases the true Hutchinson type is rarer. In only
three cases (2, 10 and 14) origin of the malignancy from a keratosis is stated.
Most of the incidences belong to the multiple form frequently distributed all
over the body. But only in two instances (cases 1 and 22) true multiple benign
basal-celled growths seem to be present; in four cases (2, 5, 6 and 10) the biopsy
showed squamous-cell cancers.
(7) So far as the predominance of the multiple type of epithelioma goes,
* To the 24 cases of Table VI may be added one case of Ayres and Anderson (1934); these
authors mention one case of Bowen's disease and another case of epithelioma, but the latter may
be identical with case 1 in Table VI. Besides,there are some doubtful cases reported, such as four
from Henry (cit. Hueper, 1942) in workers exposed to an arsenic-containing powder. Hueper
(1942) assumes a somewhat higher number of incidences (34), but it seems he has counted some
cases twice over.
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multiplicity seems more pronounced than in the therapeutic instances. But
there are at least four cases with single growths (cases 1, 2, 5 and 6).
(8) Among the relatively small number of occupational arsenical epitheliomas
four or five instances of pulnonary cancer are reported (cases 15, 16, 17, 18
and 20, the last perhaps identical with one of the former), whereas among the
so numerous medicinal cases only two occurred. It is unrcertain whether this
is a mere coincidence, or if the irritation of the respiratory tract by arsenical dust
is responsible. Unfortunately these cases are not reported fiully; it is not
mentioned whether melanosis and keratoses were present. A special committee
was constituted to examine the problem (Merewether, 1943).*
The treatment of occupational arsenical cancer is the same as that in non-
occupational cases. Of course the prophylaxis is here still more important.
Therefore in many countries social-hygienic measures have been taken for the
protection of the workers (Balthazard, 1930):
Prohibition of employment of women and young persons in factories and
workshops in which arsenic is handled.
Notification of all cases of arsenical poisoning in factories and workshops in
Great Britain by the Factories Act, 1937. Special notification ofarsenical cancer
seems not to be required (some other forms of cutaneous cancer, such as tar
cancer, are notifiable-Statutory Rules and Orders, 1919, Vol. I, p. 710).
Preventive technical measures in the factories, such as avoidance of dust,
use of dust-proof clothes and respirators, prohibition of meals taken in the work-
rooms, provision of adequate facilities for washing, etc. (in Britain, Factory and
Workshop Act, August 17, 1901, Part IV, 75; Factories Act, 1937, Part IV,
47 and 48).
Regular medical inspection of the factories and workshops. Workers with
beginning arsenical keratosis or other signs of arsenicism are forbidden to con-
tinue their work, but have to receive compensation for loss of income.
The most simnple and at the same time the most efficient way to deal with
arsenical occupational cancer would be to abolish the general use of arsenic-
containing material generally. That has been done partly by the prohibition
of the use of arsenical colours in house painting, in wall papers, etc. As now
nearly all occupational cases are caused by arsenical anti-parasitics and insecti-
cides, the replacement of these by modern arsenic-free compounds such as DDT
would settle the whole question.
D. ARSENICAL CANCER IN ANIMALS (EXCEPT EXPERIMENTAL CANCER).
The first mention of the occurrence of chronic arsenicism in animals is again
by A. Paris in 1820. He reports that in the neighbourhood ofthe copper-smelting
works of Cornwall and Wales horses and cows commonly lose their hoofs, and
not infrequently suffer from cancerous affection of their rumps. This assertion,
quoted over and over again, occasionally even with unfounded additions, has
been strongly criticized by Kennaway (1942, 1943; see also Hueper, 1942b,
1943). He objects that no attempt was made to show that arsenic was the
active substance, and that the carcinomatous nature of the alleged tumours
never has been established. Besides, the story of Paris has not been confirmed
* The members of the Arsenic Committee of the Medical Research Council are Professor M. J.
Stewart (Chairman), Professor A. Bradford Hill, Dr. Donald Hunter, Dr. S. A. Henry, Sir Ernest
Kennaway, Dr. A. N. Currie and Dr. Joan Faulkner (Secretary).
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by later reports from that area. So Paris's report should never again be quoted
as an example of arse~nical cancer in animals.
In the district of Freiberg (Saxony) smelting works for many decades affec-
tions of horned cattle are known as "Huettenrauchkrankheit" (smelting fume
disease). The clinical symptoms consist of chronic diarrhoea, cough, sclero-
dermia, chronic squamous eczema, paralytic weakness and emaciation. These
symptoms led to the thought that they may be caused by chronic arsenic
poisoning. This hypothesis was confirmed by the demonstration of arsenic in
the organs of the diseased cattle (Haubner, 1878, cit. Prell 1936/37; Wobst,
1925; Hofmann, 1937,- cit. Kennaway, 1942, 1943). But no case of cancer is
mentioned in these observations.
Since 1930 extensive arsenical injuries have been observed among wild
animals (red deer, roe deer, hares and foxes) in the Tharandt forest, also in the
region of Freiberg. The disease, most marked in deer, is characterized by
loss ofhair, blackening ofthe underlying skin, thickening ofthe stratum corneum
and extreme emaciation. In the preceding years many bee-swarms were lost,
and the beekeepers attributed that to an intoxication by the smelting fumes of
Halsbruecke and Muldenhuetten, 16 and 18 km. away. Prell (1936/37) was
able to confirm this view by finding in the pollen up to 8.8 mg. per cent arsenic,
in the dead bees up to 0.0011 mg. per bee (= 1.3-2.6 mg. per cent), the lethal
dose for a bee being 0.0001-0.0002 mg. So he concluded that the beekeepers
were right, and supposed that the disease of deer was due to the same cause.
He emphasized the similarity of the symptoms with those of arsenical poisoning
in man, drawing attention to the horny warts sometimes scattered oVer the skin.
Besides, he often found a considerable amount of arsenic in the stomach (e.g.
47 mg. per cent in a hare), in the hair (up to 1.2 mg. per cent), less in the liver;
sometimes no arsenic could be detected. Prell says nothing about occurrence
ofrealepitheliomas. But Hofmann (1937, cit. Kennaway, 1942) discovered in the
course of his investigations one case of cancer in a roe. Kennaway (1942),
in his criticism of Hueper's view, pointed out that this single case among 143 deer
and 27 hares exposed to arsenic gives, of course, no basis for the occurrence of
arsenical cancer in animals.
A high mortality of bees and fish was also reported from Reichenstein
(Kathe, 1937).
Nieberle (1939) described the occurrence of endemic carcinoma of the nasal
mucosa in a highly inbred flock of Hampshire sheep in the Limbach estate in
the remoter neighbourhood of the smelting works again of Freiberg in Saxony.
Although in the tumours, in the brain and in the liver only extremely minute
amounts of arsenic (0.01 mg. per cent) were found, Nieberle thinks that "a
certain connection of this disease with the locality and with an injury by arsenic
can scarcely be excluded." This cautious conclusion does not support Hueper's
assertion that an environmental type of arsenical carcinoma has been observed
in animals (Hueper, 1942; Kennaway, 1942).
E. EXPERIMENTAL ARSENICAL CANCER.
It has been tried to prove the carcinogenic property ofarsenic by experiments
in animals- especially after the successful experiments with tar and its con-
stituents. Different animals were used and different ways of application.
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Local Application on the Skin.
Leitch and Kennaway (1922) painted a solution of potassium arsenite in
alcohol (1.8 per cent, later 0.12 per cent) three times daily on the skin of 100
white mice through a long period. Most of the mice died within three months.
In one ofthe survivers after 86 days a tiny wart appeared on the spot of applica-
tion, after 98 days a second. The wart developed into a metastasizing squamous-
cell epithelioma. In a second series (Leitch, 1923) not a single positive result
was obtained. It is difficult to explain why only a single experiment was
successful. Spontaneous epitheliomas of the skin are very rare in mice, and the
localization on the very spot of application seems to prove that the cancer in
this case was caused by the administration of arsenic. The fact that no more
positive results were obtained may partly be explained by the difficulty in keeping
the animals alive for a sufficient time. Probably there must be-besides the
administration ofarsenic-some other unknown local or general factorsinfluencing
the success of such experimnents. Lipschuetz (1924), repeating these experiments
of painting with an alcoholic solution of arsenious trioxide, recorded only hyper-
keratoses and pigmentations but no malignancy. Raposo (1928) painted the
inner surface of the ears of rabbits with a mixture of 10 per cent arsenic trioxide
and vaseline. Besides hyperkeratoses and papillomas in several cases he obtained
a cancroid in one case. It is not reported whether controls with vaseline alone
were performed.
Oral Application of Arsenic.
Leitch and Kennaway (1922) obtained negative results in rats and mice,
Maisin (1934) in mnice. Cholewa (1934), feeding 10 mice with arsenic for one
year (0.05-0 1 mg. daily), observed in two ofthe animals blastomas of the lungs;
in one rabbit a sarcoma of the ear after 6 months. In the experiments of Finner
and Calvery (1939) with dogs and rats fed with arsenious trioxide and with
arsenates, pathological changes developed but no growth is reported. Hueper
(1942a) experimented with congenitally hairless rats; in a series of 10 animals
he obtained in one rat surviving for 21 months a cancer oftricho-epitheliomatous
structure. Nothing is said about the frequence of spontaneous cancers in these
animals; it is only stated that they develop normally papillary warts in their
hyperkeratotic skin (that was the reason why Hueper used them for his experi-
ments).
Parenteral Application of Arsenicals.
Bierich (1922), as well as Moeller (1923) and Lipschuetz (1924), injecting
white mice hypodermically with Fowler's solution, had negative results. Askanazy
and Girod (1926) injected rats with arsenious acid; in one of these animals after
some months an osteoid sarcoma developed from the follicle of a cysticercus.
White (1927) reported five negative experiments in chickens. Schinz (1942)
made deposits of (? metallic) arsenic by injecting it in the thighs of rabbits.
In one animal after six years a pulmonary giant-cell sarcoma developed. Spon-
taneous malignancies are said to be quite rare in rabbits. Ebert (1929) observed,
after intradermal application of a small dose of arsphenamine given to a man of
63, microscopical changes which he describes as "precancerous," similar to
Bowen's disease.
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As the experiments with arsenic alone did not give definite results, other
ways were tried.
Puccinelli (1930a) found very little influence of arsenic on the appearance of
spontaneous primary lung tumours in mice.
Many authors studied the effects of arsenicals on pre-existent tumours in
animals. The results were widely divergent. Some investigators, as Sticker
(1911), Funk (1915), Bierich (1922), Moeller (1923), Rosen (cit. Schiller, 1926),
and Schiller (1926) found no effect. Montemartini (1928) reported an inhibitory
effect of intravenous injections on transplanted cancers in mice.
Others observed a stimulating effect-Antonoff (1928) on Flexner-Jobling
rat carcinoma, Califano (1931) on Teutschlaenders strain in chickens; Hueper
and Itami (1933) think that intravenous injections of neoarsphenamine were
leading toward increased malignancy of spontaneous tumours in mnice. Dustin
and Gregoire (1933) experimented with mnice bearing sarcomas type Crocker; as
soon as 9 hours after injection of sodium cacodylate they observed a "veritable
explosion caryocinetique" in the transplanted tumour (see p. 231).
Other investigators studied the influence of arsenic on the development of
experimental tar cancer. Schiller (1926) reported that arsenic prevented the
precancerous changes in the skin of tarred mice from developing in carcinoma;
but it did not influence a fully established tar cancer. Puccinelli (1930a) found
a slight delaying action of arsenic trioxide on the appearance and growth of tar
cancer in white mice. On the other hand, Ciechanowski, Morozowa and Wilhelmi
(1925) observed a distinctly accelerating effect of oral ingestion of potassium
arsenite on'the development of tar carcinoma in rabbits.
Following the theory that arsenic may be favourable to the development of
growth from embryonic cells, other investigators combined the ingestion of
arsenicals with inoculation or implantation ofembryonic cell material.
Carrel (1925) started from the observation that the filtrable agent of the
Rous sarcoma is able to transform in vitro macrophages into sarcoma cells.
Supposing that this filtrable agent is produced by the cells through the influence
of a non-specific chemical substance, he injected 16 chickens with a mixture of
embryonic chicken pulp and arsenious acid. In four of these fowls after a few
days fatal fusicellular sarcomas developed. The tumours contained a filtrable
agent resembling a virus. Carrel suggested that the arsenious acid had caused
the formation by the tissues of this agent.
These sensational experiments were repeated by many investigators; but
only some of them had similar results.
Fischer (1926) reported such a similar result in a chicken which was
inoculated with embryonic spleen tissue cultivated in a medium containing a
very small quantity of arsenic trioxide. White (1927) confirmed Carrel's results;
the sarcomas arose from the embryonic tissue, not from the tissues of the host.
Haagen (1928) also repeated Carrel's experiments, with a positive result; in
addition he injected normal monocytes from chickens together with very dilute
solutions of arsenious acid in 24 fowls; after three weeks rapidly growing metas-
tasizing and transplantable sarcomas of the Rous type developed in 16 of the
animals. Petroff and Krotkina (1928) injected 97 rats with embryonic pulp
together with a suspension of arsenious acid; in three of the rats six months
later sarcomas appeared. It seemed improbable that these were spontaneous
tumours as they arose on the spots of injection. On the other hand the authors
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reported the development of sarcomas after injection of embryonic pulp alone;
so the aetiological role of arsenic in these experiments is not clear (spontaneous
tumours were very rare-only one in 300 rats). Krotkina (1934) observed
metastasizing transplantable growths after injection of embryonic pulp in a rat
previously treated with arsenic.
But all the other authors repeating Carrel's experiments were not able to
confirm his results:
Pentimilli (1926), Deelmann (1928), Maisin and Dupuis (1929), Kauffmann
(1929), Felloni (1930), Laclau and Pillado-Matheu (1930) and Lapidaria. Only
small embryomas (teratomata) occurred sometimes but no cancers.
Negative results in rats and mice were obtained by Collier and Hartnack
(1929), Puccinelli (1930a, b), McJunkin and Cirkit (1929). McJunkin and Cirkit
succeeded only in one out of 50 rats in getting a cystadenoma suggesting
malignancy.
Some authors, such as Deelman (1928), Maisin and Dupuis (1929) and Begg
and Cramer (1929), suggest that Carrel's results were possibly due to minute
contamination with traces of Rous' sarcoma virus, not to the presence of
arsenic.
Askanazy (1926) examined the influence ofarsenic on the growth ofembryonic
tissues (stomach, intestine) transplanted into the stomach of rats receiving a
small quantity of Fowler's solution with the drinking water. After 11 months
a fusicellular metastasizing sarcoma of the stomach developed in one out of
nine rats; in two others an adenocystoma appeared after 13 and 14 months
respectively, also on the spot of implantation; whereas in 18 controls without
arsenic the transplants disappeared except in one case in which a small
sarcoma ofthe liver arose. Askanazypointed out that forthe genesis ofblastomas
the presence ofseveral factors may be necessary: besides a general constitutional
predisposition (" allgemeine Koerperbereitschaft ") and a local predisposition
(represented in these experiments by the embryonic tissue), a third factor, an
irritant of oligo-dynamic efficiency, e.g. arsenic.
Fischer-Wasels (1928, 1929) and his co-worker Buengeler (1930) combined two
supposed carcinogenic factors in adifferentway. Theyproducedchronic arsenicism
by feeding or injecting rabbits or mice with potassium arsenite for many months;
then they injected scarlet red oil into the skin or (in female mice) into the breast,
or they made local burns to induce local regenerative processes. Among 18
rabbits, in one a cancer of the skin developed; and in 5 mice (= 25 per
cent) adenocarcinomas of the breast, all controls remaining negative. Spon-
taneous cancers of the breast were rare in these mice (only 4 cases among 2000
animals). The authors' interpretation was that chronic arsenic poisoning had
produced a general pre-disposition for cancer after a sensitizing period of some
months, the local procedure a local anlage. Further they found out that the
general disposition for growth in these experiments with arsenic was characterized
by certain changes ofthe metabolism ofthe tissues, proved byWarburg's methods:
decrease of oxygen consumption (checking of the respiration), increase of
anaerobic formation of lactic acid, and by aerobic glucolysis.
Summarizing the experiments on animals it can be stated that arsenic alone
has given only doubtful results. Difficulties were caused by the occurrence of
spontaneous tumours in the animals, by the high toxicity of arsenic leading to
an early death of the animals, and by the fact-well known from clinical ex-
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perience-that arsenic has a very long latent period for the production of
malignancy, usually surpassing that of the average life of the animals. The
combined experiments-arsenic plus embryonic cells or arsenic plus local in-
fluences on the tissues-have proved more successful. No critical objections to
these experiments seem to have been put forward so far.
F. PATHOGENESIS OF ARSENICAL CANCER.
Even now a really satisfactory theory of the pathogenesis of arsenical cancer
does not exist, although many clinical observations and much experimentalwork
are available.
It is a fact that arsenical malignancy is very often preceded by other manifes-
tations of arsenical poisoning, especially keratoses and pigmentation. There-
fore, arsenical cancer might be conceived as a "second disease" in the sense
Roessle used this term.
Stelwagon, Gilchrist (cit. Hueper, 1942b), Dubreuilh (1910) and de Silva
(1918) held the opinion that arsenic is not directly responsible for the cancer,
but only for the development of the keratoses. "C'est l'arsenic qui fait la
k6ratose, mais la keratose evolue ensuite spontan6ment vers le cancer" (Du-
breuilh). This view was supported by the fact that keratoses of different origin
sometimes undergo malignant transformation as well, e.g. keratoses due to
X-rays, radium, irradiation, senile keratoses and leukoplakia oris.
This view was opposed by Schamberg (1907a): "The mere fact that there
is an intervening hyperkeratosis does not relieve arsenic from the responsibility
of the production of the malign disease." He stressed the fact that the vast
majority of keratoses (congenital keratoses, tylosis, clavi, etc.) are not in the
least inclined to become malignant. Besides; this keratosis hypothesis is
insufficient, because it is now well established that many arsenical growths arise
in previously normal skin.
Stewart (1934, cit. Hueper, 1942b) suggests that the pigmentary disturbances
set up by arsenic may be related to the development of malignancy. It has
been referred to that melanin contains cyclic hydrocarbons which might be
carcinogenic. But in the majority of cases of arsenical cancer abnormal pigmen-
tation is missing.
An explanation of the carcinogenic property of arsenic has to start from the
pharmacological qualities of that poison; unfortunately they are still far
from being clear.
It is known that arsenic has local as well as-after its resorption-general
effects.
Local effects of arsenic.
Arsenicworking as a local irritant inhigh concentrations causesnecrosis. That
local irritation can play a role in the causation of malignancy is generally
accepted. Further, it is certain that in some cases of chronic arsenicism,
especially in occupational cases, signs of external irritation occur: eczema of
hands, conjunctivitis, perforation of the nasal septum, etc. But the usual
arsenical cancer of the skin cannot be caused by such a direct irritation; for
it does not appear at the sites of application. If that be the case, the cancer-
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at least in the medicinal cases-would be expected in the mouth, oesophagus,
stomach and in the intestines; frequent cancer of the jaws would be expected
after the common use of arsenic by dentists, but not localization on the skin.
Besides, the nearly always negative result ofexternal experimental application of
arsenic speaks also against local irritation as the main etiological factor.
So arsenical cancer differs essentially from other kinds of malignancy, such
as tar cancer, X-ray cancer, radium cancer, in which the main effect is seen at
the site of application (Semon, 1922; Guggenheim, 1933,). But it must
be remembered that Murphy and Sturm, in mice subjected to painting with
tar, observed an increased incidence ofpulmonary cancer, and thatsimilarresults
were reported by Schabad (1935) and Cook, Haslewood, Hewett, Hieger, Kenna-
way and Mayneord (1937). That seems to show that tar, besides its well-known
local action, has also a carcinogenic property after its resorption.
Only a few observations were advanced by some authors as an indication
that local external irritation may occasionally play a part in arsenical malignancy.
It was suggested that in some occupational incidences malignancy arose on the
place of application (Ullmann, 1930; Fassrainer, 1936; Aitken, 1944).
Eggers (1932) quotes especially the cases of sheep-dip cancer as caused by
constant irritation of the skin by arsenical dust; but the distribution of the
lesions in these cases was mainly the same as in medicinal multiple superficial
epitheliomas (see p. 223). The occurrence of pulmonary cancer in workers
exposed to inhalation of arsenical dust was also attributed to local irritation,
but' without real proof. Besides, the occasional occurrence of local "pre-
cancerous" changes after injection of arsphenamine (Ebert, 1929) may be
mentioned, and the very rare positive experiments with external application
in animals (see p. 226).
General Pharmacological Effects ofArsenic.
Hermann (1879), Schmiedeberg (1906) and Heubner (1907) suggested a
paralysis of the capillaries as the fundamental general pharmacological effect
of arsenic after its resorption. They attributed to it the frequent inflammations
of the mucous membranes and of the skin. But it is not clear in which way
such poisoning of the capillaries could lead to malignancy. Besides, the view
of these authors was opposed by others (Heffter and Keeser, 1927).
Ringer and Murrel (1878/79) declared arsenic to be a poison to all nitrogenous
tissues. And since then many investigators held the view that the basic effect
of arsenic is its action on the metabolism of the cells.
Binz and Schulz (1879) suggested that the action of arsenic is connected with
the mutual transformation which arsenious acid (As203) and arsenic acid
(As205) undergo in the presence of living protoplasm; they pointed out that
the effects of arsenic result from the development of active oxygen originating
in these processes, stimulating the cells eventually to exhaustion and death.
Brooke and Roberts (1901) supported this oxidation hypothesis as the best
explanation of the facts. But it seems that the supposed increase of cellular
oxidative processes has not sufficient experimental basis. Even the famous
basal experiments of Binz and Schulz have been criticized; the reduction of
As205 has been proved, but not the oxidation of As20O3 (see Heffter and Keeser,
1927).
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In contrast to the oxidation theory, it is known for a long time that arsenic
in very small quantities checks the processes of oxidation and reduction in the
body (Onaka, 1911). That may result in an increase of body weight and body
fat, often aspired to and achieved in the therapeutic use of the drug; increase
of body protein and bone tissue was observed too (Weiske, 1875).
Barry, Bunbury and Kennaway (1928) demonstrated in vitro such a
retarding action of arsenic upon three different oxidation-reduction processes,
namely: hypoxanthine-xanthine oxidase of rat or mouse-skin, oxidation of
acetaldehyde with colloidal platinum, and the system propylaldehyde (or acetal-
dehyde), glycerine and phosphate. The authors themselves emphasize that
one cannot with any certainty compare reactions in the test-tube with changes
in the human skin, which require months and years. But they are in accord
not only with the just-mentioned results of Onaka and similar results of Dresel
(1926 and 1928), Banga, Schneider and Szent Gyeorgyi (1931), and of Victorisz
(1931) and others, but also with the above-mentioned work of Fischer-Wasels
(1928 and 1929) and Buengeler (1930), who found in animals predisposed to
cancer by ingestion of arsenic a decrease of oxygen consumption and increase of
anaerobic formation oflactic acid.
Barry, Bunbury and Kennaway express the idea that arsenic may induce
cancer not by any direct action, but by causing accumulation in the tissues of
some (carcinogenic) organic compounds which would otherwise be oxidized or
reduced to other forms.
Bunsen had qualified arsenic as a "protoplasmic irritant." Many authors
stick to the view that it acts as an "auxetic," by direct chemical stimulation of
the epidermal cells leading to their proliferation and "cancerization " (Bland-
Sutton, 1916; Osborne, 1925; Ullmann, 1930). Dustin and Piton (1925, 1929)
and Piton (1929) observed after injection of arsenicals (especially cacodylate of
soda) in mice numerous mitoses in the thymus, in the lymph-nodes and in the
Lieberkuehn glands-" action caryocinetique." Rocmans (1930) attributed this
effect to an alkalosis, but this view was criticized by Dustin (1930). On the other
hand Throne and Myers (1935) have found in some patients with arsenic
retention and (non-malignant) lesions ofthe skin a rise in the CO2 content of the
blood suggesting an alkalosis.
Ullmann (cit. Mayer, 1933, and Throne and Myers, 1935) reported at the
International Congress of Dermatology, 1930, that a solution of one part of
arsenic in 40 millions of water, i.e. 0.0025 mg. per cent, added to embryonic
cells acts on them in a tumour-forming manner; he asserts that this action on
the cells of the hair sheaths and walls of sweat glands explains the development
of arsenical cancer.
To explain the so well marked predilection of arsenical cancer for the skin
one has to remember that arsenic has a special affinity for structures ofectodermal
origin. After ingestion it accumulates in the epidermis, sweat and sebaceous
glands and their ducts, hair follicles and hairs. Both Bruenauer (1921) and
Osborne (1925) were able to identify it there with the histochemical method.
Some authors ascribe this affinity to a special relation of arsenic to the keratin
containing large amounts of sulphur (cysteine, etc.).* So it may be understood
* See Labes, 1929, and Rosenthal and Voegtlin, 1930.
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that arsenic acts in these places as an irritant, causing keratinization and possibly
malignancy.
Certain authors asserted that the keratoses originate from the orifices of the
sweat glands (Ullman, 1930; Bruenauer, 1921), and suggest that this fact is
connected with the excretion of arsenic in the perspiration. But this view is
not generally confirmed (Brooke and Roberts, 1901).
One of the difficulties in understanding the pathogenesis is the often very
prolonged interval between cessation of the poison and starting of the malignancy
(see p. 210). Some authors doubt whether after such a long time arsenic
can still be present and act in the skin. Ullmann (cit. Hueper, 1942b, p. 54)
suggests that the cells are "cancerized" during the exposure to arsenic, but
remain quiescent for a long time. But the example of argyrosis shows; as
Franseen and Taylor (1934) remark, that a drug can remain in the skin for a
lifetime; and the presence of arsenic in the skin after a very long time was
demonstrated by chemical and histochemical methods (Montgomery, 1935).
Another fact to be explained by the theory is that arsenic produces epithe-
liomas only in very few of the many persons exposed to that poison. Many
thousands of patients are receiving this drug, but in comparatively few
arsenical keratoses develop, and in still fewer epitheliomas (Wile, 1912; Sulz-
berger, discussion to Bloom, 1936; Satenstein, ibid.). And in the positive
cases the dose of arsenic as well as the duration of the latent period and the
type of epithelioma show very great differences. Ebert (1929) observed pre-
cancerous changes after injection of arsphenamine only in certain persons.
And in analogy the attempts to produce experimental cancer with arsenic in
animals were successful only exceptionally.
All these facts suggest that in "arsenical cancer " arsenic is not the only
aetiological factor; others must be present too. On this point all authors seem
to agree (Schamberg; 1907; Wile, 1912; de Silva, 1918; Askanazy, 1926;
Buengeler, 1930; Milch, 1932; Frost, discussion to Ayres, 1934).
Some observations suggest that the individual reactivity to arsenic shows a
marked variability (Schondorf, cit. Hueper, 1942, Throne and Myers, 1935).
Throne and Myers have suggested that these differences may be related to
variations in the excretion of the poison. Cornbleet (discussion to Montgomery,
1941) found that patients showing arsenical keratoses take a longer time to
excrete a given amount of arsenic than control patients; he concluded that in
such patients the drug is retained in the epidermis for protracted periods so as
to irritate and to produce keratoses and cancer.
Other authors suggest a predisposing local abnormality of the skin, perhaps a
local sensitivity (idiosyncrasy) to arsenic analogous to contact dermatitis.
Investigations with patch tests (Sulzberger, discussion to Bloom, 1936) had no
conclusive results.
Another fact suggesting a special sensitivity of certain individuals is the high
frequency of psoriatics among the patients with medicinal arsenical cancer (see
p. 194).
The role of heredity as a predisposing factor has been mentioned by several
authors. It is well known that hereditary predisposition is very important in
certain kinds of clinical as well as experimental ma]ignancy. It is noteworthy
that in psoriasis too a hereditary factor is well established (Case 130 in Table
I belongs to a psoriatic family). It is true that in only a few cases ofarsenical
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TABLE I.
No.
1
2
3
4
5
6
7
8
9
10
11
Author.
White (1885),
"case 1 "; Hut-
chinson (1887,.
1888) case Dr. W.
(1895, 1898, 1903)
(picture)
White (1885),
"case 2"
v. Hebra (1887),
cit. Pye-Smith
(1913)
Hutchinson (and
Tay) (1887, 1888)
Hutchinson (and
Chiene) (1887,
1888)
Hutchinson (and
Allbutt) (1887,
1888)
Lane,W. A. (1894);
see also A. D. &
S., Chic., 131, 46
Hutchinson, J.
(1894)
Hutchinson, J.
(and Bullock)
(1898, 1903)
(picture)
Hutchinson, J.
(1898)
Hartzell and Stell-
wagon (1898,
1899) (picture);
Stellwagon
(1910 ?)
12 White, J. C. (1899)
13 Hyde (1899)
14
15
16
17
Ullmann (1898,
1900) (picture)
(1917)
Crocker and Per-
net (1901)
Hutchinson, J.
(1902, 1903)
(plate)
Darier (1902), cit.
Pye - Smith
(1913b) "case 22"
Sex.
Age.
M.
44
M.
52
M.
? 50
M.
34
M.
55
F.
25
M.
60
M.
35
M.
46
F.
45
F.
35
M.
M.
F.
37
M.
60
M.
70
M.
47
Drug.
Disease.
S. Fow., S. Don.;
large *quant. beg.
20 y. ago f. 6 y.
As. apparently
many y.
As. Psor.
ably)
(prob-
As. long time.
Psor.
As. many y. Psor.
As. repeatedly.
Pemphigus
S. Fow. f. 30 y.
Psor.
As. 20 bottles, 10 y.
prev., f. some
months. A c n e
As. liberally f. many
y. Psor.
As. f. 20 months.
Epilepsy
As. f. long period.
Psor.
As. Psor.
As. Psor.
S. Fow. f. 6-7 y.
Acne
As. 40 y. ago, f. 2 y.
Psor.
As. f. long periods.
Psor. (?)
As. large quant.
Chr. bronchit.
Keratoses. Localization of
Pigmentation. epitheliomas.
Ker. p. and fingers
(corns) beg. 10 y.
ago f. 6 y.
Ker. p.
Over 100 "warts"
on the body
Ker. p. and s, feet
s. 1i y.
Ker. p. and s.
(corns)
Roughness of p.
Not stated
Ker. p.
Ker. s., legs and
elsewhere
Ker. p. and s. some
y. after taking as.
Ker. p. and s. 9 y.
aft. beg. of psor.
Ker. p. and s.
Ker. p. and s.
Ker. p. and
Pig.
Warty specks,
hands
S.
Ker. p. and s.
Ker. p. and s.
(corns). Pig.
One: r. p. on ker. beg.
1-2 y. ago.
One: betw. 1. fore- and
middle finger on ker.
One: p. suff. r. wrist on
ker. 10 y.
One: betw. fingers on
ker.
Three: nr. anus, upon
penis, groin
One: r. arm.
One: r. thigh, and other
parts on warts
One: scrot., somemonths
preceded by a wart
One: 1. s.
One: toe on ker.
Later: carc. of stomach
One: nr. crista ilei on
spot of rough skin
11 growths:
4 ulc. 1. forearm in
healthy skin
7 ulc. scrotum and
perineum
One: hand, on ker., 10
y. after stopping As.;
6 y. later two scrotum
One: above pubes.
One: back (s. 3 y.)
One: r. hand on ker.
One: below 1. breast
Num. smallsuperf. ulc. on
ker. ofhands andfingers,
consid. time after beg.
of ker.
Two: 1. heel
One: over 1. breast
One: 1. groin
One: gr. toe, on ker.
One: middle finger, app.
on ker.
One: forehead, in ker.
One: 1. heel
One: r. ankle
One: r. hand, uln. bor-
der on a speck, 2 y. ago
Two others in neigh-
bourhood
Soon after ker.
One: r. forefinger on ker.
One: back ofr. shoulder
Three: hands on ker.
One: neck
One: r. upp. eyelid
Biopsy.
Metastases.
Death.
Metas.
Death
Carc.
Death.
Carc.
Death.
Death.
Metas.
Ep.
Carc.
Metas.
Death.
Metas.
Death.
Carc.
Metas.
Bas. c. ep.
Sq. c. ep.
Sq. c. ep.
Excision.
Rec.
Carc.
I A~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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TABLE I (continued).
Author.
Brocq (1902) , cit.
Schamberg (1907)
Hut chinson,
Browne and
Blackstone (1903)
"case 4"
Schamberg (1907),
"case 1"
Hartzell*
Dubreuilh (1910),
"case 3"
Dubreuilh (1910),
"case 4"
Gray (1912)
Loewenberg (1912)
case 1," seealso
disc. to Ullmann
(1922)
Loewenberg (1912)
"case 2"
Wile (1912) (plate)
Schamberg, J. F.
(Philad. Derm.
Soc., cit. Pye-
Smith, 1913b),
"case 28"
Nutt, Beattie, and
Pye-Smith (1913
a and b)
Fordyce-McKee
(1914)
Trimble (disc. to
Fordyce-McKee,
1914)
Bland-Sutton
(1916)
33 Ullmai
(1917
casE
nn, K.
, 1932),
e 2 "
Sex.
Age.
M.
35
M.
62
M.
62
M.
55
F.
old
M.
74
F.
56
M.
50
M.
50
M.
29
M.
43
F.
29
M.
37
M.
65
F.
60
F.
33
Drug.
Disease.
As. large quant. 15
y. (ab. 10 g.
As203. Chr.
bronchit.
As. f. many y.
S. Fow. ca. 30
drops daily f. 3
months 25 y.
Psor.
As. Psor.
As. large dos. Pem-
phigus
S. Fow. large quant.
15-20 drops 20 y.
Psor.
As. 32 y.
As. Psor.
As. Psor.
As. large quant. 10
y. ago f. 2 y. f.
complexion
As. large quant.
As. f. 7 y., begin.
22 y. ago. Psor.
S. Fow. f. long per.
Psor.
As. f. long per.
Psor.
S. Fow. more or
less contin. f. 30
y. Psor.
S. Fow. 15-17 y.
ago f. 1-2 y.
Chlorosis and com-
plexion
Keratoses.
Pigmentation.
and s.,
Ker. p. and s.,
warty pig.
Ker. p. and s.
Ker. p. and
warty pig.
S.,
Ker. p. and s.
All signs of chron.
arsenicism
Ker. p. and s. s.
ab. 15 y.
No ker.
Ker. p. and s.,
backs of hands
and feet, warty
Ker. p., warty
Ker. hands and feet
diffuse and punct.
4 y. after starting
As. No pig.
Ker. trunk.
Telangiect.
Ker. p. and s.
(corns) 1 y. under
wedding ring
Ker. on the whole
body
Ker. p. Pig.
Ker.
Nothing noted
Ker. p. and s.,
warty, mult. ker.
Leukoplakia oris.
No pig.
Localization of
epitheliomas.
Two: r. p. on ker.
Two: 1. p.
One: neck
One: buttock
One: face
One:
ker.
dors. r. thumb on
One: r. p. on ker.
Carc. mammae
Biopsy.
Metastases.
Death.
Carc.
Carc.
Care.
Amputat.
Rec.
Death.
One: 1. thumb on ker. Sq. c. ep.
One: r. middle finger
2y.
Sev. les. trunk
One: nr. glut. cleft, con- Bas. c. ep.
tinuous with a patch of
psoriasis 10 y.
One: back 1. hand on a Sq. c. carc
ker. papillomatous, a. Amputat.
others on. Rec.
One: flex-side of fore- Sq. c. ep.
arm, in normal skin
One: r. p. 1 y. from Death on
a ker. interc. di,
One: 1. ring-finger on Carc.
ker. Metas.
One: r. nipple.
Num. epith. all over the
trunk
One: 1. ringfinger onker.
10 months.
One: 1. middle finger
One: pubes on ker.
Three: vulva, straw-
berry-like, s. 1 y.
14 les. back, arms, leg
One carc.
One: below 1. knee in
patch of Psor. 3 y.
One: heel, 1 y. ago
One: index, j y. ago
Later: one tongue
Carc. pf mucosa oris on
leukoplakia
Sq. c. carc.
Amputat.
Rec.
Death.
Bas. c. carc.
· -
· .
Sq. c. carc.,
pagetoid.
Death.
Discussion to Schamberg (1907). See also Pye-Smith (1913b), "case 25."
No.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
S.
234ARSENICAL CANCER
No. Author.
34 Ullmann, K.
(1917), "case 3"
35 Stillians, A. W.
(1919)
36 Pusey (disc. to
Stillians, 1919)
37 Wise, F. (1920)
Hamilton, G. R.
(1921)
Alexander, A.
(1921)
Ullmann, K.
(1922)
Ullmann, K.
(1922)
Semon, H. C.
(1922) (picture)
43 Nander (1923)
Oliver (1923)
Haxthausen, H.
(1923)
Aliferis (1924,
"case 1"
Aliferis (1924),
"case 2"
Barber, H. W.
(1925)
Schwartz (1926)
Levin, O. L.
(1926), "case 1"
(see also Ander-
son, 1932)
Levin, O. L.
(1926), "case 2"
(see also Fraser,
1929)
Herxheimer (1939)
LoalzaioIo
Sex.
Age.
M.
M.
57
M.
42
F.
46
M.
35
M.
40
M.
65
M.
42
M.
65
M.
47
M.
67
M.
70
M.
35
M.
45
M.
35
M.
TABLE I (continued).
Drug.
Disease.
S. Fow. f. 2 y.
mac. Werlhof
M.
As., large dos. f. 1
y., 30 y. ago, f.
prevent. malaria
As. Psor.
S. Fow. 20 y. ago f.
6 weeks. Pem-
phigus
S. Fow. s. 36 y. 9
months in a year.
Psor.
S. Fow. 15 y. w.
interrupt. Psor.
S. Fow. sev. y.
S. Fow. sev. y.
As. f. 7 y. Psor.
Pil. asiat. 2 g. in
1 y. Psor.
As. over a long
period. Acne
As. pills (prob.) 3
t.d. during 9 y.
beg. ab. 22 y. ago
"for the nerves"
S. Fow. and As.
pill. Psor.
S. Fow. and As.
pills sometimes in
33 y. Lichen rub.
planus
S. Fow. 6 drops 3
t.d. Psor.
Medicine cont. As.
s. 8 y. (?). Der-
matitis herpetif.
Arsphenamine As.
p. os and inject.
sev. y. Syphilis.
Psor.
As. inject. and
asiatic pills.
Dermatitis
herpetif. ?
As. f. 10 y. Psor.
Keratoses.
Pigmentation.
Acute ars. pois. 1
y. later; ker. p.
General melan.
Ker. s. 25 y.
Ker. hands
Ker. p., sacr. and
lumb. reg.
Ker. p. and s., back
of hds. (corns) s.
20 y.
Ker. p. (not s.) s.
137. Pig. s. 13 y.
Ker. (p. and s. ?)
Ker. (p. and s. ?)
Ker. p. and s.
(warty) after 7 y.
Pig.
Ker. hands andfeet.
Pig.
Ker. p. and backs
of the hands
Num. ker. trunk
and extr.; no ker.
p. and s.; begin.
4-6 y. afterstopp.
the pills
Ker.
Ker. Hyperker.
sub ungualis.
Erythrodermia
Ker. p. and s.
Pig. Chr. ar-
senical dermatitis
Ker. p. and s., fin-
gers. Hyperhidros.
General keratos.
Pig.
Ker. p. and s.,
trunk
Ker. p. and
buccal muc.
S.,
Nothing noted
Localization of
epitheliomas.
One: heel, in ker.
One: 1. p. 20 months
One: hand, in ker.
One: sacr. reg. in ker.
One: r. arm not in a
patch of psor.
One: r. thigh on a patch
of psor.
One: toe
One: leg
One: toe
One: finger
One: r. sole in ker.
14 y. after stopping
As.
Mult. ulc. both shins in
psor. spots
Forehead: non - malig.
adenomata
4 or 5 ep. on the body
Mult. (20) carc. spread
over the trunk, one in
1. ax. ulc.
One: r. knee
One: nr. crena ani (not
certain whether onpatch
of psor. or on ker.)
Five, arising from ker.,
breast, back
Three (?) fungating tu-
mours: scalp, face, ears
Two flat growths upper
arms
One: r. thumb, palmar
surf. der. from ker. les.
besides groups ofpapules
and vesicles on trunk;
some resemble Bowen d.
One: 1. chest
One: 1. arm
One: neck
One: 1. thumb
Sev., trunk
38
39
40
41
42
Biopsy.
Metastases.
Death.
Death (tub.)
Sq. c. carc.
Sq. c. carc.
(mal.
papillom.)
Bas. c. carc.
Death.
Death.
Sq. c. carc.
Amputat.
Sq. c. carc.
Sq. c. carc.
Carc.
death.
Sq. c. carc
Bas. c. carc.
Bas. c. carc.
Sq. c. carc.
Metas.
44
45
46
47
48
49
50
51
52
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TABLE I (continued).
No. Author.
53 Harbitz, H. F.
(1927)
54 Oliver and Finne-
rud (1928)
55 Fraser (1928),
"case 1
56 Hofmann (1928)
57 Ramel (1929)
58 Cole and Driver
(1929)
59 Konrad (1929)
60 Fuhs (1930)
61 Rasch (1930)
62 Haagensen (1931)
("case 1")
(photo)
63 Haagensen (1931),
" case 2"
64 Haagensen (1931),
"case 3"
65 Haagensen (1931).
"case 4"
66 Stillians (1931)
67
68
69
70
71
72
73
Doty, C. A. (1931)
Gross, P. (1931)
Milian, G. (1931),
"case 1 " (see
also Milian, 1929)
Milian, G. (1931),
"case 2"
Fischer, W. (1932)
Andrews, N. P.
(1932)
Andrews, N. P.
(1932) (disc.)
Sex.
Age.
F.
46
M.
59
M.
M.
68
M.
M.
36
F.
65
M.
55
M.
35
M.
46
M.
31
M.
58
M.
69
F.
48
F.
47
F.
M.
50
F.
75
F.
Drug.
Disease.
Arsphenamine inj.
15 y. ago. Syphilis
S. Fow. beg. 22 y.
ago f. 11 y. Acne
As. beg. 52 y. ago
f. 12 y. Chorea
As. f. a long per.
Psor.
As. pills more than
30 y. ago
As. (probably) 20
y. f. an eruption
As.-containing
mixt. s. 20 y.
S. Fow. f. morethan
20 y. Psor.
As. 30 y. Psor.
S. Fow. f. the last
15 y. w. interv.
4-10 dr. t.i.d.
Psor.
S. Fow. 8 y. Pru-
ritus
S. Fow. beg. 16 y.
ago periodically.
Psor.
S. Fow. 14 y. ago,
30 dr. day f. 6
months. Nervous-
ness
S. Fow. 30 y. prey.
f. 2 y. Psor.
S. Fow. large doses
40 y. ago, and 30
pints "psoriasis-
medic."
3 y. psor. S. Fow.
f. a long time.
Skin dis. in child-
hood
As.
As.
As. long time.
Psor.
S. Fow. 60 y. over
unknown per.
As. Psor.
Keratoses.
Pigmentation.
Ker. p. (warts) 5 y.
after starting As.
Ker. extremit. esp.
feet, back
Ker. hands and
feet, warty
Ker. hands and
finger
Ker. p. and s. s.
10 y.
Ker. hands and feet
s. 18y.
Ker. soles. Pig.
Ker. p. and s. 4 y.
after starting As.
Ker. and fiss. p.
and s.
Nothing noted
Ker. p. and fingers
warty, s. 14 y.
Nit noted
No ker.
General pig.
No ker. No pig.
Ker. Pigment.
Erythrodermia
exfoliativa
Ker. not noted.
Erythrodermia
exfoliativa
Ker. p. and s.
Nothing noted
Nothing noted
Biopsy. Localization of Bos Metastases. epitheliomas. Death. Death.
Fibrosarcoma on spot of
injection (left intersc.
reg.) 12 y. after inj.
One: lumbo-sacr. reg.
One: 1. thigh
Ab. 200 lesions of
Bowen's d. beg. 8 y.
after start. As. 8 y.;
later more les. trunk
and limbs
Several feet, back, thigh
One: hand, on ker.
(after contusion)
One: 1. p. 20 months
One: r. s. Sq. c. carc.
One: r. thenar Sq. c. carc.
Sev. ulc. hands and feet Metas.
on ker.
Two: 1. calf Sq. c. carc.
Six: fingers of both Sq. c. carc.
hands
One: 1. thumb Sq. c. carc.
Metas.
One: 1. upp. arm Bas. c. carc.
One: 1. neck, both s.
4 y.
One: nr. anus, s. ab. 2 y. Sq. c. carc.
Numerous superf. les. and der-
trunk, legs, 12 y. aft.; matitis.
s. ab. 2 y.
Sev.: trunk
One: forehead
One: r. arm.; s. many y.
A number of small les.
trunk, some ulcerated
(prob. superf. ep., see
Anderson, 1932)
(Bowen's dis. ?)
Mult. superf. epith. s. Bas. c. carc.
20-35 (?) y., 3 in
face, mult. on trunk
Proliferat. of a naevus
(melanot. sarcoma ?)
7 y. later: epithelioma Sq. c. carc.
perle6 (cheek)
Carc. of r. breast
Several: r. p. and 1. calf
Mult. superf. ep. back,
chest, thighs, 40 y.
Mult. superf. ep. (includ-
ing hands)
Sq. c. carc.
Bas. c. carc.
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TABLE I (continued).
Author.
Anderson, N. P.
(1932), "case 1
(picture) (see
Montgomery,
1935, p. 229)
Anderson, N. P.
(1932), "case 3"
MacCormac, H.
(1933a and b)
Barber (1933) (dis-
cussion to Mac-
Cormac, 1933b)
Guggenheim, L.
(1933)
Wright and Fried-
man (1933),
"case 2" (pic-
ture)
Wright and Fried-
man (1933),
"case 4"
Wright and Fried-
man (1933),
"case 5"
McNeer (1934),
"case 1"
McNeer (1934),
"case 2"
McNeer (1934),
"case 3"
Ayres, S., Jr.
(1934)
Wilhelm (disc.
Ayres, 1934)
Franseen and
Taylor (1934),
"case 2"
Franseen and
Taylor (1934),
"case 4"
Sex.
Age.
M.
75
M.
70
F.
51
M.
F.
55
M.
45
F.
40
F.
60
M.
31
M.
50
M.
37
M.
over
60
M.
M.
55
F.
67
Drug.
Disease.
S. Fow. 60 y. ago
over unknown
period
As. 17 or 18 y. ago
as tonic (nerv.
breakdown)
As. (?) 25 y. ago f.
2 y. Asthma
As. large doses 20
y. preyv. long time.
Dermatitisherpetif.
S. Fow. f. 27 y., 5
drops 2 t.d. (25
g. in 27 y.).
Epilepsy
Drops, app. As. 15
y. prey. f. 6 weeks.
Psor.
As. over 20 y. ago
f. 2 y. Psor.
As. 20 y. prey. f.
1 y. Psor.
S. Fow. 22 y. ago,
30 drops d. f. 6 m.
S. Fow. 20 y. ago,
5 drops 3 t.d. f.
3 weeks. Psor.
As., beg. 17 y. ago
S. Fow. Eczema
(as student)
S. Fow. f. sev. y.
Epilepsy
As. f. 3-4 y. and
arsphenamine.
Dermatitis of
scalp
S. Fow. 40 y. prey.
for constitution
Keratoses.
Pigmentation.
Ker. p. and s., back
of hands, chest.
Cutaneous horn,
groin. Seborrhoic
keratoses
Ker. p. and s.; s. 2
y. Seborrhoic
keratoses
Ker. p. and s.
(punctate). No
pig.
Ker. p. and s. punc-
tate. Melanosis
Ker. p. and s.
Melanosis
No ker. No pig.
No ker. No pig.
No ker. No
melanos.
Ker.
Ker. hands and
extr. trunk
Ker. p. and s., dors.
of hands and feet
Ker. p. and s.
(warty) and on
trunk beg. 19 y.
ago. Telangiect.
Ker. p.
Ker. p., hands, feet,
trunk
Ker. p., arm, trunk
Localization of
epitheliomas.
Numerous les. lower part
of r. leg and foot, begin.
ab. 20 y. ago (?). Mult.
superf. ben. ep. back,
buttock (Bowen's dis. or
arsenic type of ep. ?)
One lesion ofben. superf.
ep. forehead s. 5 or 6 y.
Mult. superf. ep. trunk
andpremalignant warty
nodules arms, waist,
abdomen. Ca. cervicis
uteri
Mult. superf. ep.
Mult. (13) les., poly-
morph, beg. 15 y. aft.
start As.; not on p. and
s. Bowen-like
Twelve superficial ep.
Seven back, first s. 9 y.
Three: 1. arm
One: chest
One: 1. temple
Mult. superf. ep. w.
pearly border
One: forehead
Two: back
Three superf. ep.:
One: leg, s. 13 y.
One: neck
One: chest
Many les. beg. 5 y. ago
nr. anus and other parts
Numerous lesions: hands,
upp. extr., trunk, beg.
9 y. ago
One: r. thumb, on wart
8 y. after start. As.
One: r. foot on ker.
Four: 1. heel
Mult. ben. superf. ep. w.
pearly border, trunk,
arms, legs, plus Bowen's
dis. (?)
Superf. ep. trunk
Mult. epidermoid carc.,
app. on ker. 1. index, 1.
thumb, r. foot, back,
chest, shoulder, heel
One: ov. cr. ilei, on ker.
s. 7y.
One: neck, papillary.
One: r. thigh
Susp. carc. oesophagi
74
77
79
82
83
84
85
87
88
Biopsy.
Metastases.
Death.
Bas. c. carc.
Bas. c. carc.
Bas. c. carc.
1 Cancroid,
1 bas. c.
carc., atyp.
Mixed bas.
and sq. c.
carc.
Sq. c. carc.
Sq. c. carc.
Metas.
Sq. c. carc.
Death.
Sq. c. carc.
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TABLE I (continued).
No. Author.
89 Franseen and
Taylor (1934),
"case 5"
90 Franseen and
Taylor (1934),
"case 6"
91 Franseen and
Taylor (1934),
"case 7"
92 Franseen and
Taylor (1934),
" case 8"
93 Franseen and
Taylor (1934),
"case 9"
94 Franseen and
Taylor (1934),
"case 10"
(picture)
95 Franseen and
Taylor (1934),
"case 16"
96 Franseen and
Taylor (1934),
"case 17"
97 Franseen and
Taylor (1934),
"case 19"
98 Waugh, J., and
Scull (1935)
99 Parkhurst, H. J.
(disc. to Waugh
and Scull, 1935),
"case 1
100 Parkhurst, H. J.
(ib.), "case 2"
101 Robinson, S.
(1935)
102 Montgomery, H.
(1935), "case 1"
103 Montgomery, H.
(ib.), "case 2"
Sex.
Age.
M.
63
F.
50
M.
51
M.
53-
M.
47
M.
37
M.
34
F.
53
M.
53
F.
58
M.
34
M.
42
Drug.
Disease.
S. Fow. 10-15 y.
prev., 5 drops t.i.d.
for 2 y. Psor.
"Dr. Greene's Ner-
vine" 29 y. ago.
Nervousness, epi-
lepsy
As. 2m.
As. 15 y., 6 drops
3 t.d. Skin dis.
S. Fow. quite a
period. Epilepsy
S. Fow. beg. 14 y.
ago, up to 15 drops
3 t.d. f. 10 y. w.
interv. Psor.
(hered.)
S. Fow. Asthma
As. 32 y. prey. f.
3 y. off and on.
10 y. prey. f. 2-3
months. Psor.
S. Fow. in boyhood
f. a short t.
Acne ?
S. Fow. 5-7 drops
3 t.d. f. more than
3 y. Ataxia ?
As. from time to
time. Psor.
As. Psor.
S. Fow. s. 12 y.
Psor.
S. Fow. beg. 10 y.
ago f. 5 y., 1-26
drops 3 t.d., total
1200-1450 c.c.
Psor.
S. Fow. in early
childhood f. 6 y.
Eczema
Keratoses.
Pigmentation.
Ker. p.
Ker. whole bosly
(incl. mons pubis)
Mult. ker. whole
body, hands and
feet
Ker. p. and s.,
hands, warty face
Ker. p. and s.
shortly after
stopp. As.
Ker. p. and s. beg.
8 y. after starting
As.
Ker. trunk, no ker.
p. and s.
No ker. p. and s.
Ker. p. and s.
punctate. Pig.
Ker. hands
Ker. hands
Ker. p. and s.,
punctate
Ker. p. and s. s. 7
y. Pig.
Ker.
Two ker.
reg.
Localization of
epitheliomas.
27 lesions, back, trunk,
thigh
One: 1. shoulder
One: 1. middle finger
and 1. index (papillary)
One: neck on ker.
One: 1. foot (suspic.)
One: 1. groin
One: 1. thumb on ker.
One: 1. ring finger
Carc. pancreat.
One: back of hand, beg.
13 y. after starting As.
temp. One overthefirstthoracic
vert.
Beg. age of 51
One: nose
One: forehead
One: 1. temp. reg
One: r. upp. arm
One: 1. upp. arm
Two: hip
One: back, with pearly
border
Sev.: back
One: ulc. above nipple
Mult. (ab. 12) superfic.
ep. on the body, esp.
reg. iliaca
Superf. epitheliomatosis
widespread
Superf. ep.
One: nose
One: sole papillom.
One: 1. foot on ker.
Sev.: 1. palm
One: nr. anus
One: scrotum
One: 1. s. fr. ker. 8 y. ago
7 y. later: num. superf.
ep. on trunk,
and one superf. ep.
Later: intraur. ep.
Later: bronchial care.
Biopsy.
Metastases.
Death.
Sq. c. carc.
Sq. c. carc.
Metas.
Death.
Sq. c. carc.
Mixed bas.
sq. carc.
Sq. c. carc.
Bas. c. carc.
Ep. aden.-
cystic.
Bas. c. carc.
Metas.
Death.
Bas. c. carc.
Bas. c. carc.
Sq. c. carc.
Metas.
Sq. c. carc.
Sq. c. carc.
Sq. c. carc.
Sq. c. carc.
Sq. c. Bowen
Bas. c. carc.
Sq. c. carc.
Death.
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TABLE I (continued).
Author.
Montgomery
(1935), "case 4"
Montgomery
(1935), "case 5"
Montgomery
(1935), "case 6"
Trow (disc. to
Montgomery,
1935)
Rosen (disc. to
Montgomery,
1935)
Alderson (1935)
Ayres, S., Jr.
(1935)
Bloom (1936)
Fassrainer (1936)
(see also Straa-
ten, 1935)
Anderson (1937)
Ayres, S., Jr.
(disc. to Ander-
son, 1937)
Traub (1937)
Robinson (1937)
Rauschkolb
(Arday) (1938)
Barber (1939)
Haldin-Davis
(1939), disc. to
Barber (1939)
Voss (1939)
Sex.
Age.
M.
63
F.
44
M.
50
M.
50
M.
40
M.
50
F.
59
F.
M.
35
M.
F.
68
M.
M.
49
M.
37
F.
F.
62
Drug.
Disease.
"Ascato" 30
prey. Asthma
Y.
S. Fow. 30 y. ago,
3-16 drops 3 t.d.
f. more than 1 y.
Chorea
S. Fow. as a child.
Chorea
S. Fow. f. 2-3 y.
Fits
Arsphenamine f.
ulc. in the mouth
As. pills, 15! daily,
each cont. 0'1-0'4
mg., beg. 27 y.
ago, f. 7 y. Psor.
S. Fow. 49 y. ago
over a long per.
Psor. (?)
As. Psor.
S. Fow. 1 y.
Eczema, hands
"Ascato" 2-3 y.
Asthma
As.
As. 40 y. ago f.
4 y. Acne, psor.
S. Fow. f. many y.
Psor.
S. Fow. f. 25 y. off
and on. Psor.
As. f. 10 y. Epi-
lepsy
As. f. 20 y. Epi-
lepsy
S. Fow. As. pills
20 y. ago. Psor.
Keratoses.
Pigmentation.
Ker. p.,fingers,20y.
afterstart. As. No
pigment. Verruc.
senil.
Nil noted
Ker. p. and s.
Slight pig.
Ker. p.
Ker. p. and s.
(corns).
Ker. trunk, nose,
ear, eyelid. Pig.
Ker. p. and s.
(punct.)
Ker. p. and s. No
pig.
Ker. hands (warts)
Ker. p. and s.
Arsenical ker.
Ker. (?) leg
Ker. p. and s. and
body s. 1 y.
Pig.
Ker. p. and s.
Telangiect.
Ker. p. and s.
Ker. p. and s., etc.
Pig.
Ker. trunk but not
p. and s. Pig.
Biopsy. Localization of Bitast .
epitheliomas. Metastases. Death.
Several p. and fingers,
some on ker. s. more
than 6 y.
One: scalp
More than 50 superf. ep.
trunk "arsenical type"
6-7 y.
One: r. axilla 15 y.
"arsenical type simu-
lating Bowen"
Num. superf. ep.
One: a typical verruc.
lesion
One: trunk and back
Two: back of fingers
app. on ker.
Oral mucosa
Mult.'polymorph. plaques
over the body
One: abdom., superf.,
later malign.
One: fourth finger later
malign.
One: neck
Superf. ep. s. 12 y.
Two (or more ?): face,
forehead, neck, scalp;
sim. Bowen
Superf. ep. back
Ep. p. and s. on ker.
One: hand, from a wart
One: 1. index
5'y. later: r. index beg.
as a wart
Mult. ben. superf. ep.
scattered over trunkand
upp. port. of arms
One: palm
One: axill.
.
Mult. polymorph. les.,
trunk, leg, face beg. 4
y. after medic. of As.
One: back
One: 1. sole (ulcus). Pig-
mented macular scaling
areas over the body
About 50 superf. ep.
trunk, upp. extr. beg.
8 y. ago
Numer. superf. ep. trunk
At least one: abdomen
18 polymorph. les. trunk,
reg. genit. rima ani,
thigh, ab. 7 y.
Sq. c. carc.
One: bas. c.
ep. chang-
ing in sq.
Sq. c. care.
Bas. c. care.
Metas.
Sq. c. care.
Bas. c. carc.
Bas. c. care.
Metas. (sq.
c. ep.)
Bas. c. carc.
Sq. c. carc.
Bas. c. carc.
Bas. c. carc.
Bas. c. carc.
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TABLE I (continued).
Author.
Ryan (1939)
Goeckerman and
Wilhelm (1940)
Anderson (disc. to
Goeckerman and
Wilhelm, 1940)
Applestein (1941)
Rodgers (1941)
Robinson (disc. to
Rodgers, 1941)
Montgomery and
Waisman (1941),
"case 1 "
Montgomery and
Waisman (1941),
"case 2"
Montgomery, R. M.
(1942)
Peck (1942)
Ayres, S., Jr.
(1943)
Anderson (1943)
Ebert and Otsuka
(1943)
Sex.
Age.
M.
52
M.
70
M.
21
F.
60
M.
55
M.
49
F.
69
F.
42
M.
45
M.
56
F.
47
F.
42
Drug.
Disease.
As. over 12 y. Sto-
mach trouble
S. Fow. f. 10 y.
Epilepsy
As. 7 y. prey. f.
6 m.
S. Fow. beg. 35 y.
ago; f. 25 y. 5-10
drops 3 t.d.
Psor.
S. Fow. many y.
ago
As. (?)
S. Fow. 26 y. at
least once yearly
until 9 y. ago.
Psor.
S. Fow. 20 y. ago
f. 5 weeks and 1 y.
ago for 1 week
S. Fow. 30 y. ago.
Acne
As. drops 31 y.
Psor. hered.
Asiat. pills 33 y.
ago f. 5 y. Psor.
As. inject. 20 y.
prey.
As. as child
Anaemia
Keratoses.
Pigmentation.
Ker. p. and s. and
scatt. of tr. and
extr. s. 16 y.
Ker. p. and s. 14 y.
after starting As.
2 y. later trunk
(Bowen-like)
Ker. p. and s.
Nothing noted ab.
ker. Pig.
Telangiect.
Nothing noted ab.
ker.
Arsenical ker.
finger, etc.
Ker. p. and s. s.
14 y.
Num. ker. trunk
and extr. (nothing
noted ofp. and s.).
No pig.
Ker. fingers, soles
(punctat.). Leu-
copl. oris
Ker. p.
Ker. p. and s.
(punctate)
Ker. s., no p.
Localization of
epitheliomas.
Biopsy.
Metastases.
Death.
Mult. superf. ep. (?)
One: r. ear
One: chest, trunk
(Bowen-like)
Papilloma ureteris et
vesicae
Mult. superf. ep. trunk
One large fungating in
groin
Carc. of tongue
Mult.: epitheliomatosis
One: 1. shoulder s. 8 y.
One: r. temple
One: chest, papill., prob.
not malign.
Forehead, thighs, r.elbow,
scalp
Mult. ben. superf. ep.
s. 4y.
L. shoulder
Little finger
Many: back of hands,
scalp, r. knee and legs
Back (cauliflower-like)
One: finger
Sev.: 1. p. on ker.
(thumb), 15 months ago
Numerous trunk and upp.
extr.
Sq. c. carc.
Bas. c. carc.
Sq. c. carc.
Bowenoid ?
Bas. c. carc.
Mixed c.
carc.
Sq. c. carc.
Sq. c. carc.
Sq. c. carc.,
ars. type;
some Bas.
c. carc.
One: r. cheek Bas. c. carc.
One: r. fossa, nasal Bas. c. care.
One: r. temple, papillo-
mat. w. pearly border
Num. lesions trunk and Sq. c. carc.
extr. s. 2 y. (Bowen-
like).
One verruc. les. on little Sq. c. carc.
finger s. 5 y.
Multiple: dors. ofr. foot, Bowen dis.
1. knee, 1. thigh, dors. (biopsy).
of 1. hand, wrists s.
10 y.
Two: 1. p. on ker. Sq. c. carc.
Ab. 30 ben. superf. ep. Some: sq.
polym orph., trunk, r. c. carc.
rm. f. 8 y.
Dry scaly lesions trunk,
s 3-4 y.
L. shoulder Bas. c. carc.
L. hip
One: r. hip s. 14 y. Bowen d. or
intraepid.
ep.
One: 1. chest
No.
121
122
123
124
125
126
127
128
129
130
131
132
133
..l
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TABLE I (continued).
No. Author.
134 Anderson (1943)
135 Wilhelm and
Goeckerman
(1943)
136 Laymon (1943)
137 Hall (1944)
'138 Barney (1944)
139 Dowling (disc. to
Glen, 1945)
140 Russell and Klaber
(1945), "case 1"
141 Russell ani Klaber
(1945), "case 2"
142 Semon, H. C. (disc.
to Russell and
Klaber, 1945)
'143 Semon, H. C. (ib.),
"case 2"
Sex.
Age.
Drug.
Disease. Keratoses.
Pigmentation.
Localization of
epitheliomas.
I' II
M.
50
M.
72
F.
61
F.
61
M.
46
Old
F.
53
F.
44
M.
As.
As. drops and in-
ject. 10 y. ago
As. drops 17-22
(?) y. prev. f. 5 y.
Anaem. pernic.
As. drops (?) small
quant. 45 y. ago
f. short time (only
7'5c.c.) f. com-
plexion. Later
As. for syph.
orally and i.v.
Black pills 20 y.
ago intermitt. f. 6
months. Psor.
As. years
Psor.
before.
S. Fow. 3 drops
3 t.d. beg. 13 y.
ago; total 37,000
drops. Epilepsy
S. Fow. in Br-mixt.
f. 30 y.; total
79,000 drops-700
gr. A2sO3. Epi-
lepsy
S. Fow. large dos.
up to 1 dr.
3 t.d. Dermatitis
herpetiformis
As. for 14 y. Psor.
Ker. p. and s.
(punctate)
No ker. Pig.
Ker. p. and s.
No ker. p. and s.
Ker. p. and s. one
y. later. Ker.
trunk
Nothing noted ab.
ker.
No ker. p. and s.
Pigment. (no
"raindrop ").
Mult. seborrh.
warts, mollus.
Ker. p. No rain-
drop-pigment.
Mult. seborrh.
warts and mollus.
fibros.
Ker. feet
One: superf. ep. r.
shoulder
Later: two, scrotum
Mult. ben. superf. ep.
trunk
At least 30 superf. ep.
trunk
Several superf. ep. s.
11 y.
One: scap. reg.
One: beg. in patch of
psor. 10 y. ago
Num. superf. polymorph.
ep. trunk, extrem.
One: below axill.
One: scrotum
Later: carc. oesophag.
Numerous flat ep.
Polymorphic lesions
Oneindurated ulcer chest
12 y. after starting As.
Two plaques with pearly
edge over sternum
Mult. ep. w. pearly rolled
edges truink, shoulder,
thighs
Indurated plaque r. f.
iliaca
One: r. nipple
Carc. bronch. (skin not
affected)
One: 1. foot on ker.
Biopsy.
Metastases.
Death.
Bowenoid,
Pagetoid.
Probably
bas. c. carc.
Bas. c. carc.
Sq. c. carc.
Sq. c. carc. ?
Death,
general
carc.
Sq. c. carc.
Bas. c. carc.
(cyst. deg.).
Sq. c. carc.
Death.
- 0.O. NEUBAUER
TABLE II.
Keratoseogen Mult. superf. and Combination of
except comb. Bowen except keratoseogen and
w. mult. superf. comb. w. kerat. mult. superf.
(53 cases). (48 cases). (13 cases).
Fingers,hand,wrist, 45 = 84-9% . 4 = 8.3% . 13 = 100%
toes, foot, ankle
Arm, thigh, leg . 6 = 11-1% . 21 = 43.7% . 4 = 30.8% .
Scrotum . . 3 = 5.7% . 1 = 2.1% . ..
Penis . . . 1-9% . ....
Vulva . . 1= 1.9%. 1= 2.1% ..
Pubes, groin, peri- 3 = 5- 7% . 3 = 6.25% . 1 = 7-7%
neum, anal reg.
Neck . . . 5= 7.5% 4= 8-3% . ..
Head . . . 3 = 5.7% . 13 = 27.1% . 1 = 7-7% .
Trunk,icl.shoulder, 8 = 15.1% . 40 = 83.3% . 10 = 76.9% .
axill., breast, hip,
buttock, sacr. reg.
"Alloverthebody" 1 = 1.9% . 3 = 6.25% . 2 = 15.4% .
Extracutan.. . 3 = 5.7% . 2 = 4.2% . 1 = 7.7%
Epith. on
patches
ofpsor.
(7 cases).
. .
6 -= 85-7%
2 = 28.6%/
3 = 42.9%
All
cases
(136 cases).
63 = 46'3%
41 = 30.1%
6 = 4.4%
1= 0.7%
2= 1-5%
11= 8.9%
.. . 8= 5.9%
. . 19 = 14.0%
1 = 14-43% . 63 = 46'3%
.. . 7= 5-1%
. 12 = 9.6%
In this Table different localizations in the same region are counted only as one even if, e.g., both
hands and both feet are affected.
TABLE III.
All cases.
10cases = 8- 7%
28 ,, = 24-3%
35 ,, = 30-4%
24 ,, = 20-9%
17 ,, = 14-8%
1 case = 0-9%
115 cases
Males.
5 cases = 6.25%
19 ,, = 23.75%
25 ,, = 31-2%
16 ,, = 20-0%
14 ,, = 17.5%
1 case = 1.-25%
80 cases
Females.
5cases= 14.3%
9 ,, = 25-5%
10 ,, = 28.6%
8 ,, =22.9%
3 ,, = 8.6%
35 cases
TABLE IV.
Hamilton (1921, case 38)
Schwartz (1926, case 49) .
Anderson (1932, case 24) .
,, ( ... , 25) .
Ayres, Jr. (1934, case 85) .
Montgomery (1935, case 97)
,, ( ,, ,, 99)
Anderson (1937, case 113)
Montgomery and Waisman (1941, case 122)
, (,, ,, 128)
TABLE V.
Case 102, keratoseogen ep. (sq.)
,, 103, ,, ,, (sq.)
,, 104, mult. ep. as. type
(a) hand (sq. ep.) .
(b) trunk (sq. ep.)
(c) back (sq. ep.) . ,, 105, mult. ep. as.type (sq.)
Case ofsuperf. ep. (1935, p. 232)
(bas. c.)
Ditto (bas. sq.)
Ditto (Bowen )
Case 106, ben. superf. ep.
(a) bas. c. ep.
(b) Verrucous les. (sq. c.)
Case 127, superf. ep. as. type
(a) several (sq. and bas. c.)
(b) thenar (sq. ep.)
Case 128, num. les. as. type
trunk, arms (sq. ep.)
As2O, in growth.
Chem. Osborne.
0 +
0 +
8, 6 mg. %
0.18 mg. %
0
0
0
0-5 mg. %
0.024-430 mg. %
++
++
+
++
Traces
0
0-00025 mg.%
0.007 mg.%
0-0027-0-0048 mg.% (in
dried substance)
0 035 mg.%
0
0.037 mg.%
0
0
As,O,a in normal skin.
Chem. Osborne.
'
+
0
0
0
. 077 mg. %
++- .-
. 0008 mg. %
+,+
2.2-27.5 mr. % + . 100 mg. % (?)
20-30 years
31-40 ,,
41-50 ,,
51-60 ,,
61-70 ,,
71-80 ,,
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TABLE VI.-Occupational Arsenical.
Case. Author.
MINERS, SMELTERS:
1 Anderson (1932),
"case 2," fig. 3.
(See also Ayres
and Anderson,
1934)
2 Schaerrer (1934)
3 Migavi (1935)
4 Andrews (disc. to
Goeckerman and
Wilhelm, 1940)
SHEEP-DIP WORKERS
5 Eve (1913). (See
also O'Donovan,
1924, "case 2 ")
6 Porter (1913).
(See also O'Dono-
van, 1924, "case
3")
7 Legge (1923),
"case 1"
8 Legge (1923),
"case 2"
9 Legge (1923),
"case 3"
10 Legge (1924, 1934),
"case 4"
O'Donovan (1924a,
1928), "case 1
(picture)
11 Bridge (1926)
12 Bridge (1926)
13 Bridge (1930)
14 Legge (1934),
" case 3"
15 Merewether (1943)
16- Merewether (1943)
18
INSECTICIDES:
19 Legge (1925)
Bridge (1928)
Sex. Sex. Employment. Age.
M.
M. 34 y. previous in
51 smelters in Mexico
for 8 y.
M.
M.
40
M.
35
M.
53
M.
53
M.
39
M.
44
M.
61
M.
49
M.
57
M.
48
In silver mining or
smelting
16 y. in smeltery in
Japan
In a copper mine
20 y.
fact.
skin
20 y.
fact.
38 y.
fact.
33 y.
fact.
22 y.
fact.
26 y.
fact.
in sheep-dip
Pig. ofentire
in sheep-dip
Keratoses.
Pigmentation.
Ker. p. and s.
Ker. p. and s. 10 y.
after starting work
Many typical ker.
p. and s.
Ker. p. (not s.)
Pig. all over the
body
in sheep-dip Warty ker.
in sheep-dip Ker. p.
in sheep-dip Ker. p.
in sheep-dip Ker. warts
· .
46 y. in sheep-dip
fact.
22 y. in sheep-dip
fact.
43 y. in sheep-dip
fact.
In sheep-dip fact.
19 y. in emerald
green fact. and 10
y. further exposure
to As.
Ker. p. Pig.
Pig.
Localization of Biopsy.
epithelioma. Metastases. Death.
Mult. ben. superf. ep.
chest and back s. 7
years
Sq. c. ep. Metas.
Epitheliomas
One over 1. clay. 2 y.
Bas. c. carc.
and dys-
keratoses.
Sq. c. carc.
Metas.
Sq. c. carc.
One: 1. shoulder beg. as Sq. c. carc.
a wart 8 months prev. Death.
One abdomen
Mult. growths armpit,
groin, thigh, scrotum,
sacrum, arms, feet
Warty conditions back
of hands, r. groin, 1.
buttock
One: 1. temple on a wart.
Four growths prey., 1.
clavicle, abdomen, 1.
flank, thigh
Subsequent primary
growths:-
One: r. shoulder (36 y.
after beg. employm.)
One: neck (5 y. later)
One: 1. upper arm (5 y.
later)
One: penis
Warts back of hands, r.
groin, 1. buttock
One: 1. axilla.
2 y. later, one below
1. knee
Carc. not
sure.
..
Carc. not
sure.
Sq. c. carc.
Metas.
death.
Metas.
death.
Metas.
death.
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TABLE VI.-Occupational Arsenical (continued).
Case. Author.
20 Hopkins and Van
Studdiford (1934)
(picture)
21 Franseenand Taylor
(1934) "case 1"
22 Franse enandTaylor
(1934) "case 3"
v. Pein (1938a, b)
Bridge (1939)
Sex.
Age.
M.
5
Negro
M.
59
M.
51
M.
40
Employment.
~l
Living in cotton
wool farm; fields
sprayed with in-
secticides
30 or more y. em-
ployed w. As-prep.
f. fruit trees
27y. ago empl. w.
As-prep. for fruit
trees
Vintager, 4 y. use
of" Nospran"
Empl. in factory of
As-containing in-
secticides
Keratoses.
Pigmentation.
Ker. p. Pig. hands.
Ker. p. a. s.
Ker. p. warty
Ker. p. a. s.
Melanosis, Perfor. of
nasal sept.
Localization of
epithelioma.
Mult. ep. face s. 4 y.,
exulcerated
Mult. scaly les. ov. the
body s. 40 y. 4 bas. c. ep.
ear, upp. lip, arm, leg
One carc. neck. Mult.
carc. trunk
Mult. ulc. carc. skin
Warty growths ov. the
body. Primary carc. of
r. lung
ABBREVIATIONS.
As., arsenic; bas., basal; beg., beginning; betw., between; carc., carcinoma; c., cell(ed);
ep., epithelioma; interv., interval; ker., keratosis; 1., left; les., lesion(s); m., month; metas.,
metastases; mult., multiple; nr., near; num., numerous; p., palms; per., period; pig.,
pigment(ed); psor., psoriasis; r., right; rec., recurrence; s., soles; S. Don., Sol. Donovan; S.
Fow., Sol. Fowleri; sev., several; sq., squamous; superf., superficial; ulc., ulcer(ated); y., years.
cancer in Table I is the occurrence of malignancy in other members of the family
mentioned (cases 4 and 104, in neither of them affecting the skin). Such
occasional coincidence of course cannot prove anything. On the other hand a
systematic investigation of the hereditary conditions in arsenical cancer has
never been carried out.
The possible role of embryonic germs in the sense of the Cohnheim theory of
cancer was the starting-point of the above-mentioned experiments of Carrel
(1925) and Askanazy (1926).
Askanazy, stressing the necessity to assume the co-operation of several factors
for the genesis of arsenical cancer, ascribed to arsenic the role of an irritant of
oligodynamic efficiency, acting alongside a general constitutional predisposition
(" allgemeine Koerperbereitschaft ") and a local predisposition (e.g. presence of
embryonic tissue). Fischer-Wasels (1928, 1929) and Buengeler (1930), on
the other hand, suggested that arsenical poisoning after a latent sensitizing
period causes a general disposition for cancer (" allgemeine Geschwulstdisposi-
tion "), marked by certain metabolic changes (see p. 228), preparing the
ground for the development of malignancy out of a local anlage (" locale Gesch-
wulstanlage ").
Given such a general disposition, or provided even pre-cancerous lesions
(keratosis) have developed, then the subsequent development of an epithelioma
at that site may be facilitated by the action of non-specific external irritation,
23
24
Biopsy.
Metastases.
Death.
Resid.
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such as by rubbing, scratching, or other slight traumatism (Wile, 1912; de
Silva, 1918).
Eggers (1931), summarizing the facts, concludes that arsenic is an agent
that seems to cause a decided increase in the predisposition to cancer, so
that an added element of irritation, which in ordinary conditions would be inade-
quate, comes into operation.
This work was carried out with the aid of a grant from the Medical
Research Council.
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